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Abstract
The application of principles from evolutionary biology has long been used to gain new
insights into the progression and clinical control of both infectious diseases and neo-
plasms. This iterative evolutionary process consists of expansion, diversification and
selection within an adaptive landscape — species are subject to random genetic or epi-
genetic alterations that result in variations; genetic information is inherited through
asexual reproduction and strong selective pressures such as therapeutic intervention
can lead to the adaptation and expansion of resistant variants. These principles lie at
the center of modern evolutionary synthesis and constitute the primary reasons for
the development of resistance and therapeutic failure, but also provide a framework
that allows for more effective control.
A model system for studying the evolution of resistance and control of therapeutic
failure is the treatment of chronic HIV-1 infection by broadly neutralizing antibody
(bNAb) therapy. A relatively recent discovery is that a minority of HIV-infected
individuals can produce broadly neutralizing antibodies, that is, antibodies that in-
hibit infection by many strains of HIV. Passive transfer of human antibodies for the
prevention and treatment of HIV-1 infection is increasingly being considered as an
alternative to a conventional vaccine. However, recent evolution studies have uncov-
ered that antibody treatment can exert selective pressure on virus that results in the
rapid evolution of resistance. In certain cases, complete resistance to an antibody is
conferred with a single amino acid substitution on the viral envelope of HIV.
The challenges in uncovering resistance mechanisms and designing effective com-
bination strategies to control evolutionary processes and prevent therapeutic failure
apply more broadly. We are motivated by two questions:
x• Can we predict the evolution to resistance by characterizing genetic alterations
that contribute to modified phenotypic fitness?
• Given an evolutionary landscape and a set of candidate therapies, can we com-
putationally synthesize treatment strategies that control evolution to resistance?
To address the first question, we propose a mathematical framework to reason about
evolutionary dynamics of HIV from computationally derived Gibbs energy fitness
landscapes — expanding the theoretical concept of an evolutionary landscape orig-
inally conceived by Sewall Wright to a computable, quantifiable, multidimensional,
structurally defined fitness surface upon which to study complex HIV evolutionary
outcomes.
To design combination treatment strategies that control evolution to resistance,
we propose a methodology that solves for optimal combinations and concentrations
of candidate therapies, and allows for the ability to quantifiably explore tradeoffs in
treatment design, such as limiting the number of candidate therapies in the combi-
nation, dosage constraints and robustness to error. Our algorithm is based on the
application of recent results in optimal control to an HIV evolutionary dynamics
model and is constructed from experimentally derived antibody resistant phenotypes
and their single antibody pharmacodynamics. This method represents a first step
towards integrating principled engineering techniques with an experimentally based
mathematical model in the rational design of combination treatment strategies and
offers predictive understanding of the effects of combination therapies of evolutionary
dynamics and resistance of HIV. Preliminary in vitro studies suggest that the com-
bination antibody therapies predicted by our algorithm can neutralize heterogeneous
viral populations despite containing resistant mutations.
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Introduction
“The power of Selection, whether exercised by man or brought into play under nature
through the struggle for existence and the consequent survival of the fittest, absolutely
depends on the variability of organic beings. Without variability, nothing can be ef-
fected; slight individual differences, however, suffice for the work, and are probably
the chief or sole means in the production of new species." - Charles Darwin, 1868.
1.1 Background and Motivation
The modern synthesis. The core of current evolutionary theory was forged seventy
years after Charles Darwin’s On the Origin of Species [20], when statisticians and
geneticists began laying the foundation for what is now called the ‘modern synthesis’.
This allowed the process of evolution to be described mathematically as the change
in frequencies of genetic traits in a population over time, uniting Darwin’s concept of
natural selection with a newly formed field of Mendelian genetics [30, 33, 103]. This
theoretical foundation and its corresponding quantitative methods provided support
to better understand the tenets of evolutionary theory — that variation arises through
random genetic mutation, is inherited by offspring and these together with natural
selection leads to adaptation and speciation.
Evolutionary biologists have since expanded upon the modern synthesis frame-
work, drawing concepts and methods from other fields. The discovery of DNA as
the material foundation for the encoding and the hereditary transmission of genetic
2information, became the driving force of evolutionary theory. It transformed the no-
tion that selection was associated with phenotypic trait variation to being a function
of variations driven by genetic mutations. Since then, genetic mapping for numerous
phenotypic adaptations across multiple organisms have been established — such as
the evolution of influenza virus resistance to antivirals [80], the adaptation of wing
shape in [74] and the genetic basis resistance of malaria in humans [34, 39].
Evolution and disease. More recently, the application of evolutionary concepts has
been extended to the study of both infectious and neoplastic disease, giving new in-
sights into their progression and clinical control [62, 71, 72]. The underlying processes
are equivalent to other evolutionary models — cells or virus are subject to random
genetic mutation that result in variations; genetic information is inherited through
asexual reproduction and strong selective pressures such as therapeutic intervention
can lead to the adaptation and expansion of resistant variants. Genetic instability
of neoplasms drives single base sequence changes, chromosomal rearrangements and
gene fusion, and these can confer a selective advantage when the resulting phenotype
exhibits both a proliferative advantage and a defect in DNA repair [55]. Non-genetic
adaptation and phenotypic plasticity can be induced via oncogene inhibition, enabling
the survival in cancer cells during initial therapy and thereby promoting residual dis-
ease. Recent studies in EGFR mutant lung adenocarcinoma reveal that NF-κB sig-
naling is rapidly engaged upon initial EGFR inhibitor treatment to promote tumor
cell survival [7].
The 1987 FDA approval of azidothymidine (AZT), a nucleoside analog reverse-
transcriptase inhibitor (NRTI) for the treatment of chronic HIV infection, was one of
the first signs of therapeutic promise in the treatment of chronic human immunod-
eficiency virus type 1 (HIV-1) infection — this treatment significantly reduced viral
replication in patients and led to clinical improvements [29]. However, the ability
of HIV to rapidly evolve drug resistance was soon observed in patients treated with
AZT— the genetic basis for their resistance was explained with the existence of three
amino acid substitutions in the reverse transcription gene [50]. It was not until the
1995-1996, that that the subject of resistance was addressed with the development of
3a new class of protease inhibitors (PIs) [61], that when combined with two NRTIs,
introduced the concept of highly active antiretroviral therapy (HAART). The treat-
ment of chronic HIV infection with HAART is considered one of the great successes of
modern medicine in that it radically changed clinical outcomes successfully reducing
both patient viral loads to virtually “undetectable" levels, transforming HIV from a
fatal disease to one that is a manageable chronic illness [18].
The success of antiretroviral combination therapy in controlling evolution of HIV
has provided insight into how the evolutionary processes of other disease models could
be controlled for progression and management of therapeutic resistance [4, 94, 99].
With the recent introduction of targeted therapies for the treatment of certain cancers
[36], new questions surrounding the effectiveness of tailoring treatments to an individ-
ual patient’s tumor and its implications with respect to the emergence of driver mu-
tations and resistant phenotypes are being raised. Specifically, these small molecule
inhibitors and monoclonal antibodies exploit particular genetic addictions and vulner-
abilities of cancer cells, establishing an environment in which the occurrence of mildly
drug resistant cells can develop an evolutionary advantage over those for which the
therapy is targeted [23, 27, 41, 97]. Clonal expansion of these evolutionary advan-
tageous cells is exacerbated by the presence of considerable genetic intra-tumor het-
erogeneity already present in treatment-naive patients, contributing to resistance and
the need for principled approaches to the design of combination targeted treatment
strategies.
Toward a Principled Design of Treatment Strategies. These disease models
illustrate more generally the challenges in uncovering resistance mechanisms and de-
signing effective combination strategies to control evolutionary processes that lead to
resistance. Similar evolutionary processes are involved in the context of HIV-1 and
selection of resistant mutants with respect to broadly neutralizing antibody (bNAb)
therapy. In this thesis, we focus our attention to this particular application, but
the mathematical techniques that we propose are relevant to other infectious and
non-infectious diseases where growth, mutation and selection are central.
Recent evolution studies on HIV-1 have uncovered that bNAb monotherapy can
4exert selective pressure on virus resulting in the rapid appearance and evolution of
resistant mutant viral population [22, 47, 100]. In certain cases, complete resistance
to a bNAb is conferred with a single amino acid substitution on the viral envelope
(Env). To address HIV evolution in this context, combination bNAb therapy has
been proposed and shown to effectively control infection and suppress viral loads
below detection in murine models [22, 47, 100].
Advances in the identification and engineering of anti-HIV-1 antibodies have pro-
duced a large set of detailed molecular structures and neutralization data generated
against a broad panel of HIV-1 strains. Can we computationally predict evolution
to resistance by characterizing genetic alterations that contribute to modified phe-
notypic fitness? To address this question, we propose a computational model to
reason about evolutionary dynamics of HIV from computationally derived fitness
landscapes—linking the notion of genotype to phenotype in a quantifiable manner.
The second question we ask is, given a fitness landscape and a set of candidate
therapies, can we computationally synthesize treatment strategies and control evo-
lution? The rational design of combination antibody therapies for HIV treatment
involves the exploration of a large mutational space in the context of an ever growing
number of candidate antibodies — experimentally screening their combinations and
concentrations to effectively control evolution to resistance becomes increasingly in-
feasible. To address this, we require a scalable methodology that can take into account
increasing amounts of HIV/bNAb resistance data, bNAb pharmacodynamic models
and HIV mutational dynamics. To this end we propose a scalable and computation-
ally tractable algorithm that solves for optimal combinations and concentrations of
bNAbs to neutralize virus in light of viral evolution while simultaneously allowing
the designer to tailor treatment strategies in light of viral composition, maximum
achievable doses, number of bNAbs used and ability to support pharmacodynam-
ics/pharmacokinetic fluctuations, modeling and experimental error.
We briefly discuss prior computational work in addressing this problem, and follow
with the thesis outline and contributions.
51.2 Prior Work
Mathematical approaches. There have been numerous attempts to address evo-
lution of resistance with respect to therapeutic intervention from a mathematical
perspective within multiple disease contexts. Many computational results address
evolution to resistance by employing analytic methods and/or simulations on small
scale stochastic evolutionary dynamics models. The Michor lab [63] recently showed
the effects of different erlotinib dosing strategies in the presence of pharmacokinetic
fluctuations on the evolution of resistance of non small cell lung cancer through simu-
lations of a stochastic evolutionary dynamics model. To address tumor heterogeneity
by rational combination therapy design, Zhao et al. [105], propose a static multi-
objective optimization formulation that is agnostic to evolutionary dynamics but that
models the effectiveness of independently acting, additive drugs on different initial
tumor populations. Proposed combination treatments were confirmed experimentally
for different tumor initial conditions in a murine lymphoma model [106].
The first models describing evolutionary processes in the context of HIV, were
inspired largely in part by Manfred Eigen’s original quasi species model [26] and have
since been proposed to study evolution, antigenic drift [70, 71]. Recent results by
Rosenbloom et al. [87], show that simulations of an evolutionary dynamics model
of HIV infection subject to changes in antiretroviral dynamics due to adherence are
consistent with clinical studies.
Control theoretic approaches. The challenge of designing treatment protocols
that prevent escape is one that has been addressed by control theoretic methods. For
cancer therapy, results in this spirit apply methods from optimal and receding horizon
control [3, 16], as well as gain scheduling [2], to synthesize treatment protocols that
are robust to parameter uncertainty, an inherent issue in all biological systems. In
the context of HIV and antiretroviral therapy, Hernandez-Vargas et al. [25] propose
a discrete time formulation that allows for the design of switching therapy strategies
to delay the emergence of highly resistant mutant viruses. There have been several
attempts as well to address nonlinear HIV infection dynamics using model predic-
6tive control (MPC) to design optimal antiretroviral drug dosing strategies [56, 108].
Recent results in [84] and [8] consider a simplified bilinear model and the optimal
control problem is shown to be convex over a finite horizon for a predefined set of
initial states.
1.3 Thesis Contribution and Outline
In this thesis, we explore two questions in the evolutionary biology of disease: Can we
predict the evolution to resistance by characterizing genetic alterations that contribute
to modified phenotypic fitness? Given a fitness landscape and a set of candidate ther-
apies, can we computationally synthesize treatment strategies and control evolution?
We focus our application to the antibody treatment of chronic HIV infection, but the
mathematical techniques that we propose are relevant to other infectious and non-
infectious diseases. Many of the contributions of the following chapters are based on
a number of publications [42, 43, 44], indicated below.
Chapter 2: Evolutionary Dynamics on Computationally Derived Fitness
Landscapes. We propose a computational model to reason about evolutionary dy-
namics of HIV on computationally derived fitness landscapes. Our approach combines
well-utilized HIV dynamical systems models, incorporates infection and antibody neu-
tralization dynamics, a mutation process, and a method that uses energy minimization
calculations on structural information to quantify fitness differences between sensitive
and resistant strains. Specifically:
1. We propose and develop an extension of the least absolute shrinkage and selec-
tion operator (LASSO) to identify mutational phenotypes and uncover potential
escape mutants from neutralizing anti HIV antibodies.
2. We develop a biophysical model based on Gibbs free energy of binding derived
from energy minimization calculations on structural information to quantify
fitness differences between sensitive and resistant HIV strains.
73. We develop an HIV evolutionary dynamics model to include infection and neu-
tralization reaction rates based on computed Gibbs energy fitness landscapes.
Chapter 3: Robust Control of Evolutionary Dynamics. Chapter 3 presents
three algorithms for the principled design of targeted combination drug treatment
strategies that explicitly account for the evolutionary dynamics of a generic disease
model, where the drugs under consideration are non-interacting and exhibit inde-
pendent additive effects. These algorithms allow the designer to quantifiably explore
tradeoffs between number of therapies used (controller sparsity), therapy concentra-
tions (magnitude of the gain) and ability to support pharmacokinetic fluctuations
(robustness to perturbations). Our contribution specifically is itemized below.
1. Our first algorithm proposes a general iterative method that uses an H∞ robust
control approach to design targeted combination therapy concentrations and is
effective in generating robustly stabilizing controllers.
2. Our second algorithm addresses large scale systems concerns lacking in the first
algorithm, presenting a scalable solution to the combination therapy problem
by reformulating it as a second order cone program (SOCP), with robustness
guarantees addressed by minimization of the induced L1 norm.
3. Our third algorithm solves the combination therapy problem subject to the
same design constraints (sparsity of the drug combination, maximum dosage and
robustness constraints) formulated as an SOCP while addressing the nonlinear
dynamics of individual drugs and of their combinations.
Chapter 4: Engineering Antibody Treatment Strategies to Control HIV.
We demonstrate our ability to control the evolution to resistance of HIV in the pres-
ence of antibody therapy, through the application of the combination therapy algo-
rithms developed in Chapter 3 as applied to experimental data derived from recent
published studies [14, 22, 47]. We also discuss a preliminary in vitro experimental
methodology and results and show that the antibody treatment strategies synthesized
with the nonlinear pharmacodynamics combination therapy algorithm described in
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Figure 1.1: Overview of the data, mathematical models and tools used in this thesis.
Section 3.5.3 controls infection despite the presence of a mixed initial population of
viruses, most of which are resistant to at least one antibody in the mix. Specifically:
1. We synthesize combination treatments and compare the respective H∞ and
the L1 combination therapy algorithms with respect to their performance and
robustness to biologically relevant uncertainty models and unmodeled dynamics.
2. We develop a high throughput in vitro experimental system to identify the repli-
cation and neutralization properties of HIV mutants and populate parameters
for our dynamical systems model, as well as test our predicted bNAb combina-
tion therapies.
3. We demonstrate successful in vitro validation of our computationally predicted
bNAb combinations on heterogeneous viral populations comprised of resistant
mutants.
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Evolutionary Dynamics on
Computationally Derived Fitness
Landscapes
2.1 Introduction
In evolutionary biology, the concept of fitness landscape serves to associate geno-
type to some measure of fitness, or phenotype. With the growing number of detailed
molecular structures and recent advances in modeling and computational approaches,
genotype-phenotype relationships are now being quantified and generated in an au-
tomated way. Thus, fitness landscapes are transitioning from a concept used for
visualization of fitness distributions, to computable, quantifiable, multidimensional
fitness surfaces upon which to study complex evolutionary outcomes.
Recent pre-clinical and clinical studies recently demonstrated that HIV can escape
from antibody mono therapy, and in some cases, combination therapy [14, 37, 47, 95].
In this chapter, we develop a computational framework that explains these observa-
tions and predicts the likelihood of certain resistant mutants in the presence of anti-
body mono therapy. Our method uses energy minimization calculations on structural
information and statistical inference on antibody neutralization data to quantify fit-
ness differences between sensitive and resistant strains and incorporates this data into
an HIV dynamical systems model of infection, mutation and antibody neutralization.
We show that our evolutionary dynamics simulations on computationally generated
10
HIV fitness landscapes have reasonable agreement with experimental findings. This
represents a first step in modeling and predicting HIV escape from antibody therapy
but has a broader application in evolutionary dynamics settings where a quantitative
relationship between genotype and evolutionary fitness can be established.
The chapter is organized as follows: in Section 2.2.1, we propose a statistical in-
ference method to uncover correlations between HIV-1 viral envelope (Env) sequence
data and antibody neutralization data. In Section 2.2.2, we compute HIV-1 fitness
landscapes using energy minimization techniques and argue that quantifying changes
to both infection and neutralization due to mutations are equally important aspects
in the study of HIV evolution to antibody resistance. In Sections 2.2.2 and 2.2.3, we
derive generalized Hill equations to express bound gp160/CD4 and gp160/antibody
as a function of the differences in Gibbs free energy of binding due to point mutations.
Section 2.2.4 connects preceding work by incorporating computed fitness landscapes
into a stochastic HIV evolutionary dynamical systems model of infection, mutation
and antibody neutralization and illustrates the applicability of these methods for the
prediction of resistance dynamics in light of antibody monotherapy for HIV.
2.2 Results
2.2.1 Statistical inference to uncover resistance phenotypes
We developed a statistical model and used this to uncover correlations between HIV-1
envelope (Env) sequence data and antibody neutralization data. In order to obtain a
model that could explain antibody neutralization data with a minimal set of residues
while taking into account irregularity in the experimental data set corresponding to
the limit of neutralization assays (Figure 2.1), we extended the well known least
absolute shrinkage and selection operator (Lasso) [98]. Our model, the saturated
Lasso (satlasso), returns a set of amino acid residues and their Env sequence loca-
tion that explains antibody neutralization data by minimizing error between model
and experimental data, penalizing large models, and appropriately weighing errors
11
corresponding to saturated experimental data. A mathematical description of the
model can be found in Section 2.4.1. Model selection is performed with 5-fold cross
validation [79].
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Figure 2.1: A. An example of the satlasso estimator as applied to 8ANC195 antibody
neutralization data. Saturated data is due to the limit of the neutralization assay and
is modeled in Equation (2.6). Red points correspond to experimental data, blue points
correspond to the estimated model.
To assess the generalization of our satlasso model, we compare the first six largest
magnitude regressors to experimentally derived data sets and find that many Env
residues known to be critical to neutralization are identified (Figure 2.2). For the
gp120-gp41 bridge antibody 8ANC195, changes in glycosylation at 276, 234 and 230
sites are found to induce large changes in neutralization [91]. Specifically, the intro-
duction of a glycan at position 230 in a wild-type YU2 HIV strain, leads to a sixfold
increase in IC50, whereas removal of 234 and 276 sites leads to a more substantial
increase in IC50 [91, 101]. Our model identifies this epitope and captures the corre-
sponding changes in IC50 through the magnitude of each regressor 276++ (-2.79),
234++ (-2.77) and 230++ (1.59) (Figure 2.2).
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Figure 2.2: The first six regressors with largest magnitude contributing to neutralization
(blue) and resistance (red) for each of CD4 binding site, V2, V3, MPER and gp120-gp41
bridging antibodies in this study, solved with satlasso using 5-fold cross validation. Overlaid
boxes correspond to amino acid changes that have been validated experimentally.
For all CD4 binding site antibodies in this study, we find that the existence of a Gly
at position 459 is most important for neutralization, confirming previous evolution
studies that mutations at position 459 confer resistance in 3BNC117 and NIH-4546-
G54W [47, 22]. Our model uncovers that an Arg at position 456 is also significant for
neutralization but less so than the site at position 459. Recently, Lynch et al. show
that a Trp mutation at position 456 has a modest effect on neutralization by many
CD4-bs antibodies with the exception of VRC-PG20 [57].
Functional studies on V3 loop binding antibodies 10-996 and 10-1074 reveal an
essential dependence on the N332 associated glycan [66]. Our model identifies this
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critical site and shows that the existence of a His or Tyr at position 330 is necessary
for neutralization of 10-1074. There is some evidence that the H330Y substitution
has no effect on neutralization of either PGT121 and 10-1074 when this mutation was
tested on Simian-Human Immunodeficiency Virus, SHIVAD8 [89].
The highly conserved membrane proximal external region (MPER) of the gp41
transmembrane subunit on HIV-1 has recently been linked to epitopes of several
broadly neutralizing antibodies 2F5, 10E8 and 4E10 [38, 88, 65]. Alanine scanning,
structural and paratope analysis each indicate that 10E8 makes crucial contacts with
highly conserved residues W672, F673, W676 and K/R683 [38]. Although our model
does not recover these particular contact sites, it does identify a Thr substitution at
671 that is shown to raise IC80 values above 20 µg/ml in otherwise sensitive JR2
virus [38]. For 4E10, our model captures both one epitope site at 671 and a known
resistant substitution at 674S [9]. The 2F5 epitope is defined by a linear segment
of gp41 residues 662 - 668 with the key binding residues at N664, K665 and Y666
[6, 109]. Our model recovers the crucial binding site at position 665 and two sites on
the epitope, E662 and A667 that each confer resistance at the IC90 level with Ala
and Gly substitutions respectively [12, 109].
Our results demonstrate that satlasso recovers residues that are critical for neu-
tralization and those that contribute to resistance for a large class of anti-HIV-1
antibodies. Despite the fact that substitutions in certain positions can mediate con-
formational or other effects within Env that may be best represented by a nonlinear
model, some changes in neutralization can nonetheless be captured by this linear
regression model.
Recent studies in viral fitness costs associated with escape mutants from the class
of CD4-bs antibodies show that viral replicative fitness may be diminished with cer-
tain single mutations on the CD4 receptor binding site on gp120 [57], Chapter 4.
This suggests more broadly that evolution to resistance can be viewed as a function
of both viral replicative and antibody neutralization fitness. We elaborate this idea
in the following section and develop a method that quantifies both aspects of viral
fitness and utilizes it to study the evolutionary dynamics of HIV in the presence of
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antibody monotherapy.
2.2.2 Gibbs Energy Landscapes Correlate With Known Es-
cape Mutations
We hypothesize that a virus’ capacity to infect and be neutralized by specific neu-
tralizing antibodies (NAbs) can be approximated by differences in Gibbs free energy
of binding associated to de novo point mutations on the envelope glycoprotein (Env)
complexed with the CD4 receptor and antibody structure. To compute fitness land-
scapes relating to viral replication and antibody neutralization, we apply an empirical
force field, Fold X [93], to evaluate the effect of point mutations on the stability, fold-
ing and dynamics on detailed Env/CD4 and Env/NAb molecular structures.
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Figure 2.3: A. Gibbs binding energy differences computed between wild type and a subset of
gp120 point mutations consisting of alanine substitutions on a subset of 3BCN117 antibody
resistant mutations. Viral fitness F∆gp/NAb, is computed by Gibbs energy of binding differ-
ences between neutralization and infection reactions and normalized with respect to largest
value (Equation 2.3) (above). Gibbs energy differences for ∆gp120/3BCN117 binding reac-
tion (middle) and the ∆gp120/CD4 interaction (below). All mutations are numbered with
respect to the HXBC2 reference genome. B. Viral fitness computed as in A for CD4 binding
site antibodies 3BNC117, 4546G54W, VRC01, VRC03, and VRCCH31. C. Fraction bound
gp120/3BNC117 and CD4/gp120 as computed with Equations (2.5) using Gibbs energy
landscapes for antibody and CD4 binding.
The resulting Gibbs free energy landscape provides an equilibrium thermody-
namic representation of the fitness of each point mutant with respect to the following
simplified binding reactions for infection and neutralization:
gp + cd4 −→ gp · cd4, (2.1)
`+ gp −→ ` · gp, (2.2)
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where the HIV membrane glycoprotein gp, binds to the CD4 receptor, denoted cd4,
in reaction (2.1), and to antibody ` during neutralization in reaction (2.2).
We compute the difference in Gibbs free energy of binding between mutant and
wild type viral glycoprotein gp160,
∆∆G = ∆Gmut −∆Gwt,
for all point mutations on the solved portions of gp160 in both CD4 and antibody
complexes listed in Table 2.2, Section 2.5.
To quantify the effects of mutations on both infection and neutralization, we define
viral fitness F∆gp/NAb as a function of the cost of the mutation (∆gp) with respect to
antibody binding minus its cost with respect to CD4 binding
F∆gp/NAb = ∆∆G(∆gp/NAb)−∆∆G(∆gp/CD4). (2.3)
To illustrate this measure of viral fitness, we compute binding energy landscapes
for CD4 binding site (CD4bs) antibody 3BNC117 using gp120/3BNC117 (PDB ID:
4JPV) and gp120/CD4 (PDB ID: 1G9N) structures and find reasonable agreement
between this measure and known resistant mutations in the presence of 3BNC117
[37, 57] (Figure 2.3, A). In particular, we note that the presence of either an Asp
at position 458 or an Ala at position 367 decreases binding to both 3BNC117 and
to CD4, simultaneously affecting the virus’ ability to infect and to be neutralized by
antibody. Binding energy differences between mutations and the CD4 receptor are
similar for both G367A and G458D (3.64 kcal/mol and 3.75 kcal/mol) whereas they
differ significantly for 3BNC117 binding (3.55 kcal/mol (G367A) and 11.15 kcal/mol
(G458D)), suggesting that both mutations could exhibit compromised viral replication
but that due to the greater difference in 3BNC117 binding, the Asp mutation at
location 458 is more likely to escape 3BNC117 neutralization. This is consistent with
our viral fitness calculations and model simulations (Figure 2.5, B) as well as previous
experimental validation showing that the Asp mutation at position 458 evolves in the
presence of 3BNC117 in murine HIV infection models [37, 57].
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To extend our analysis to other CD4bs antibodies, we compute Gibbs binding en-
ergy landscapes for 3BNC117, 4546G54W, VRC01, VRC03 and VRCCH31. Our viral
fitness calculations uncover that the most resistant substitutions across all CD4bs in
the study consist of an Asp substitution at either locations 458, 280 and 459 (Figure
2.3, B). Previous studies show that both the Asp substitutions at location 458 and
at location 280 evolve in 4546G54W and 3BNC117 monotherapy experiments [22, 37]
and abrogates neutralization by VRCCH31, and VRC01 [57]. The application of our
statistical inference model from Section 2.2.1 and previous experimental validation
[22, 37, 101] shows the importance of Gly at location 459 for effective neutralization
by all CD4bs antibodies.
More subtle differences in viral fitness differences can be uncovered by computing
Gibbs energy landscapes. We note that the Trp substitution at location 456 exhibits
a more modest increase in viral fitness (0.15-0.45) than the Asp substitution at 458
(0.45-1.0) across the CD4bs antibodies in the study, confirming recent experimental
studies that show that the Trp substitution at location 456 modestly decreases but
does not completely abrogate neutralization in all CD4bs antibodies [57].
2.2.3 Hill Functions Relate Gibbs Landscapes And Dynamical
Systems Parameters
Although analysis of detailed molecular structures may elicit molecular properties
by which resistance occurs, the pharmacodynamics of associated drug resistance are
less well understood. Therapeutic effect of resistant mutations is typically measured
as a change in IC50 relative to wild type. In the case of antiretroviral therapy for
HIV, Sampah et al. argue that inhibition can only be predicted if the shape of the
dose-response curve is known [90]. This relationship takes the form of a Hill function,
an equation extensively used in pharmacology to analyze nonlinear drug-receptor
relationships.
We derive generalized Hill equations and express the fraction of bound Env/CD4
and Env/antibody complexes formed during infection and neutralization binding re-
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Figure 2.4: A. A depiction of the molecular binding model approximating the Gibbs binding
energy between viral envelope glycoprotein and the neutralizing antibody and the CD4 re-
ceptor, using simplified binding reactions (2.1) and (2.2). B. A depiction of the evolutionary
dynamics model of HIV infection, mutation and neutralization in the presence of antibody
therapy. C. (Left) Difference in Gibbs binding energy between wild type and mutations of
the viral glycoprotein and the CD4 receptor, for a clade B virus YU2, (PDB ID: 1G9N) for
a subset of point mutations. Percent infected cells on day three post secondary infection
(dark red) and simulations of the molecular binding plus infection dynamics model using
the calculated Gibbs free energy landscape (light red) for a subset of viral glycoprotein
mutations. (Right) Three day infection simulations using the calculated Gibbs energies for
selected point mutations. D. (Left) Difference in Gibbs binding energy between wild type
and mutations of the viral glycoprotein and broadly neutralizing antibody 4546G54W, (PDB
ID: 4JKP) for a subset of point mutations. Percent neutralized cells on day three in the
presence of 10 µg/ml 4546G54W (dark blue) and simulations of the molecular binding and
infection and neutralization dynamics model using both Gibbs free energy landscapes in the
presence of 10 µg/ml 4546G54W (light blue) for a subset of viral glycoprotein mutations.
(Right) Three day neutralization dynamics simulations using calculated Gibbs energies for
selected point mutations for a range of 4546G54W antibody concentrations.
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actions, as a function of the differences in Gibbs free energy due to point mutations.
We begin by noting that the dissociation constant Kd is an equilibrium value that
can be expressed in terms of the free energy of binding, and define ∆Kmutd to be the
ratio between mutant and wild type dissociation constants:
∆Kmutd =
Kmutd
Kwtd
= ∆∆G/RT , (2.4)
where R is the ideal gas constant and T is temperature. The resulting Hill equations
model the fraction bound complexes involved in both infection and neutralization
reactions:
Rmut =
[gp]m
[gp]m+(Kwtinf∆K
mut
inf )
m
Nmut =
[`]n
[`]n+(Kwtneut∆K
mut
neut)
n ,
(2.5)
where the symbol [ ] indicates nanomolar concentration. ∆Kmutinf and ∆Kmutneut are the
difference between the dissociation constants for CD4 and antibody binding reactions
(2.1) and (2.2) between a mutationmut and the wild type viral glycoprotein as defined
by Equation (2.4).
Remark 1. We assume that binding associated with the infection and neutralization
process is noncooperative, and the corresponding Hill coefficientsm and n are approx-
imately 1. Recent experimental studies characterizing antibody neutralization across
a diverse virus panel, suggests that for CD4 binding site antibodies n ≈ 0.9 − 1.37
[92], for V2 antibodies n ≈ 0.7 and for V3 binding antibodies n ≈ 1.5. [64].
Figure 2.3 C depicts the Hill equations (2.5) associated with infection and neu-
tralization reactions for a subset of representative 3BNC117 resistant mutations and
their computed Gibbs binding energy landscapes. For highly resistant mutations most
likely to evolve in the presence of 3BNC117 like the Asp mutation at location 458, we
expect a small fraction of bound gp120/3BNC117 regardless of antibody concentration
and a moderate concentration of bound gp120/CD4, representing productive infec-
tion. More moderately resistant mutations, such as the Thr mutation at 281, requires
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two orders of magnitude increase in 3BNC117 concentration to achieve an equivalent
fraction of gp120/antibody bound complexes and neutralization as wild type virus.
This suggests that at lower concentrations of antibody, viruses with similar fitness
profiles as A281T may not be all neutralized by antibody, creating an environment
in which this moderately resistant virus can become dominant or acquire additional
mutations and achieve greater resistance [22, 37, 47, 57].
2.2.4 Evolutionary Dynamics on Quantifiable HIV-1 Fitness
Landscapes
To reason about the dynamics of HIV evolution to resistance in the presence of an-
tibody therapy, we combined computed Gibbs energy landscapes with a stochastic
evolutionary dynamical system to model infection, mutation and antibody neutral-
ization (Figure 2.4, A, B). A mathematical description of the virus dynamics and
mutation model can be found in Section 2.4.1.
In order to validate of our model, we performed simulations of HIV infection and
antibody neutralization and compared these results to replication and neutralization
assays performed on gp120 mutations subcloned into a YU2-Env/NL4.3 infectious
backbone (Materials and Methods, Section 2.4.3). Both our simulations and experi-
ments were performed under the same conditions and were found to be in agreement,
(Figure 2.4, C, D), suggesting that our proposed mathematical model of HIV infec-
tion and neutralization based on Gibbs energy landscapes can be used to reasonably
predict both infectivity and neutralization rate changes due to point mutations on
Env. Simulations of our HIV infection model (Figure 2.4, C) confirm the well-known
exponential growth dynamics of HIV infection for mutations with small changes in
CD4 binding energies. For mutations with compromised CD4 binding such as the
Lys mutation on 279 and the Tyr mutation at 280, our simulations and experiments
show significantly decreased infection rates.
To illustrate how different neutralization profiles affect the evolution of resis-
tance, we ran model simulations for a subset of Env point mutations and a range
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of 4546G54W concentrations (Figure 2.4, D). We found that certain very resistant
mutations are less likely to be affected by high doses of 4546G54W, such as the Lys
mutation on 279 and the Tyr mutation at 280, whereas the degree of neutralization
of moderately resistant mutations such as the Ser substitution at 279 is dependent
on 4546G54W concentration (Figures 2.3, C and 2.4, D). High concentrations of
4546G54W are likely to shift the evolution of viral distributions towards highly re-
sistant mutations by creating an environment in which mutations with moderate
resistance are adequately neutralized, leaving the possibility of outgrowth of highly
resistant mutants despite low infectivity. We observe this phenomenon in our evolu-
tionary dynamics simulation in the presence of another CD4bs antibody, 3BNC117
(Figure 2.5,B). Specifically, the Lys substitution at location 280 is shown to outgrow
all other mutations with lower viral fitness, despite its lower infectivity (Figures 2.4,C
and 2.5,B).
To further explore how antibody concentration could influence the composition of
viral distributions at steady state, we ran fifty stochastic simulations of our HIV evo-
lutionary dynamics model for different concentrations of 3BNC117 (Figure 2.6,A). We
observe that the shape of the stationary distributions varies as a function of antibody
concentration with broader peaks occurring at lower antibody concentrations and
higher, narrower peaks at high antibody concentrations. We use the Gini coefficient
(Materials and Methods, ss:gini) to describe the shape of the stationary viral distri-
bution, and show that it increases as a function of different antibody concentration
for multiple CD4bs antibodies (Figure 2.6,B).
To understand which mutants might evolve in the presence of CD4bs antibodies,
we ran fifty evolutionary dynamics simulations using computed CD4 and antibody
binding energy landscapes for 1664 different mutants of YU2, using constant concen-
trations of either VRC01, VRC03, 3BNC117 or NIH4546. For a starting population
of monoclonal wild type virus, we show that the evolved mutations have close agree-
ment with previously studied escape mutations (Figure 2.5, C). Specifically, our HIV
evolutionary dynamics simulations in the presence of NIH-4546 reveal the evolution
of mutations at four out of five locations uncovered in recent evolutionary studies
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on antibodies NIH-4546 and NIH-4546G54W [47, 22]. Moreover, recent experimen-
tal results show that mutations N280D, N280K, A281T, G458D, G459D evolve from
3BNC117 monotherapy [37] - our simulations demonstrate the evolution of four out
of these five specific point mutations.
A B#
Figure 2.5: A. Fitness landscapes representing the difference in Gibbs binding energy be-
tween wild type and mutations on the viral glycoprotein (∆gp120) and the CD4 receptor
(PDB ID: 1G9N) (above) and the neutralizing antibody 3BNC117 (PDB ID: 4JPV) (below)
for all amino acid substitutions on a subset of residues. Closed circles indicate binding site
locations, stars indicate residue locations for which resistant mutations have been found.
B. One simulation of the HIV evolutionary dynamics model (Equation 2.7, Materials and
Methods) on computed Gibbs energy landscapes shown in A and for a concentration of 5
µg/ml 3BNC117. The simulation is run with an initial condition 105 uninfected cells/ml,
1000 virions/ml of of wild type YU2 clade B HIV. (Below) Fitness landscape and computed
viral fitness for evolved mutations.
23
A" B"
C"
Figure 2.6: A. (Left) Fifty simulations of the HIV evolutionary dynamics model (Equation
2.7, Materials and Methods) on computed CD4 and antibody fitness landscapes for differ-
ent NIH-4546 antibody concentrations. Simulations are run with an initial condition of 105
uninfected cells/ml, 1000 virions/ml of of wild type YU2 clade B HIV. (Right) Viral dis-
tributions at day 250 for all corresponding simulations, representing the percent mutation
present in the total population at steady state. B. Gini coefficient for antibodies NIH-4546,
3BNC117 and VRC03 as a function of antibody concentration, for steady state viral distri-
butions in A. C. Viral distributions at day 250 for all 50 simulations of HIV evolutionary
dynamics for (top) 2.5 µg/ml of NIH-4546 and (bottom) 3BCN117. Filled circles represent
particular mutations that are shown to evolve experimentally [22, 47] or to be resistant
[57, 101]. Empty circles represent the residue locations at which mutations either evolve or
have compromised neutralization by antibody.
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2.3 Discussion
Recent advances in the identification and engineering of anti-HIV-1 antibodies have
produced a large set of detailed molecular structures and neutralization data gen-
erated against a broad panel of HIV-1 strains. Recent computational analysis of
antibody neutralization data has been successful in categorizing antibodies with re-
spect to their neutralization activity [32], extracting the identities of Env residues that
are necessary for neutralization [101] and uncovering antibody epitopes [73]. Here,
we report a computational methodology that utilizes antibody neutralization data
and structural information to construct HIV fitness landscapes and reason about the
dynamics of resistance. It consists of the interpretation of neutralization data us-
ing statistical inference, the construction of fitness landscapes using computational
chemistry and the development of biophysical and mathematical model to capture
the dynamics of replication, mutation and selection.
Our statistical model is able to uncover critical Env residues involved in antibody
neutralization and is consistent with recent studies in antibody resistance. It does not
identify the entire structural epitope involved in the protein-protein contact. Rather,
satlasso identifies an epitope that is involved in the function of the protein-protein
interaction, in our case neutralization.
To address virus fitness in terms of its replication and neutralization capabilities,
we computed Gibbs binding energy landscapes on gp120/CD4 and gp120/NAb struc-
tures and found a good correspondence with our experimental studies. One of the
drawbacks of using force fields to compute fitness landscapes, is that they rely on ex-
perimental data and are therefore empirical. Furthermore, Xray structures are prone
to errors due in part to the non-physiological conditions under which the structure
is determined. Setting these concerns aside, tools like Fold X are geared specifically
toward screening the effect of single nucleotide polymorphisms (SNPs) on protein sta-
bility and are therefore well suited for our problem. For non-conservative mutations
(those not involving Ala or Gly scanning), a reorganization of the protein backbone is
often necessary, requiring an exploration of alternative conformations. However, for
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large structure reconfigurations such as a deletion or creation of a glycan structure, we
observe that Fold X is not always able to capture the corresponding effects on binding
energy. In the case where glycosylation changes have a large effect on neutralization
by antibody, satlasso is likely to recover these features, as illustrated by the accurate
uncovering of the glycan dependence of 8ANC195. Therefore, the combination of
data derived from satlasso and Gibbs energy landscapes offer complementary views
on viral fitness.
We present an HIV evolutionary dynamics model that is the first to our knowl-
edge to incorporate binding energy landscapes of replication and neutralization and
that accurately predicts the evolution of point mutations in the presence of anti-HIV
antibody monotherapy. Recent evolution studies uncovered the evolution of dou-
ble mutations that conferred resistance to several antibodies [22, 47, 37]. A clear
extension to our model is to incorporate double mutations in our Markov model of
mutational dynamics however a clear limitation is the accuracy of an empirical energy
minimization in the case of such double mutations.
2.4 Materials and Methods
2.4.1 Mathematical Models
satlasso. We define the saturated least absolute shrinkage and selection operator
(satlasso) and formulate it as a convex optimization problem. We consider that
the antibody neutralization data X = Xs + Xu is comprised of saturated data Xs,
corresponding to IC50s of very resistant viruses, and of unsaturated data Xu (Figure
2.1). Observe n predictor response pairs (xi, yi) where xi ∈ Rp and y ∈ R. Forming
X ∈ Rn×p, X = Xu + Xs with standardized columns, the saturated lasso, (satlasso)
is an estimator defined by the following convex optimization problem:
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minimize β∈Rp
λ1
1
m
||yu −Xuβ||2︸ ︷︷ ︸
Error unsaturated data
+λ2
1
m
n∑
i=1
wi|βi|︸ ︷︷ ︸
Sparsity
+λ3 max(ys −Xsβ, 0)︸ ︷︷ ︸
Error saturated data
, (2.6)
where wi = 1βˆi and βˆi =
1
ξ
∑ξ
j=1 |βˆji | where βˆj is the solution to the ordinary least
squares problem for subset j.
Model selection was performed by 5 fold-cross validation. Our results exclude mu-
tations that are located in the signal peptide region, transmembrane and intracellular
regions corresponding to HXBC2-numbered residues (1-30), (685-706) and (706-end)
respectively. These locations on Env are not exposed to antibody binding and we
assume that are not subject to selective pressure by antibody.
Viral dynamics. To simulate how HIV might evolve resistance, we extended
the widely used HIV infection dynamics model [77] with a random mutation process
and included our Gibbs energy formulation to capture the effects of genomic variation
on the dynamics on infection and neutralization by antibody therapy. The stochastic
discrete time differential equation model of HIV evolution under antibody selection
is written as:
x[k + 1] = λ+ x[k]− (ηc
∑n
i Rix[k]− dxx[k])τ,
yi[k + 1] = yi[k] + (ηcRix[k] + Υi[k]− dyyi[k])τ,
vi[k + 1] = vi[k] + ((1−Ni)kvyi[k]−Nivi[k]− dvv[k])τ,
(2.7)
where x ∈ R+ is the concentration of uninfected CD4+ T cells, yi ∈ R+ is the
concentration of infected CD4+ T cells that are actively producing mutant i, vi ∈ R+
is the concentration of mutant virus i. Ri and Ni represent fraction bound ligand
associated with infection and neutralization of mutants, respectively as described in
Section 2.2.3. ηc = 104-105 is the number of CD4+ T cell receptors per uninfected
cell [51, 81]. We note that the infection binding function
27
Ri =
[gp]m
[gp]m + (Kwtinf∆Kiinf )m (2.8)
depends on the concentration of HIV glycoprotein for mutant i, and that is dependent
on virus state vi. The glycoprotein concentration for mutants i at time k is calculated
by
[gpi] = vi[k]
ηgp120
NA
, (2.9)
where ηgp120 = 14 is the number of glycoprotein molecules per virion [17, 54] and NA
is the Avogadro constant. dx, dy, dv are degradation rates, respectively, of uninfected
CD4+ cells, infected CD4+ cells, and virus. dy and dv are assumed to be equivalent
for any mutant virus. λ is the T cell generation rate, and kv is the viral burst rate,
assumed to be equal for all mutants. Υi is the number of mutants i generated by the
mutation process. Parameter values and units are listed in Table 2.4, Section 2.5.
Mutation process. The mutation process models the effects of error prone
reverse transcription allowing the genetic variability necessary for selection. Experi-
mental results indicate that single residue point mutations can cause resistance in the
presence of even the most potent broadly neutralizing antibodies [22, 47, 101], Chapter
4. Thus, we focus our analysis on point mutations on the viral envelope glycoprotein
but assume that mutations anywhere on the HIV genome are equally probable. We
do not consider mutations based on insertions, deletions or recombinations.
We allow for any number of single nucleotide changes to occur based on the reverse
transcription rate of mutation u = 3 × 10−5 mutations/base pair/replication cycle.
However, we track viruses that have at most one residue substitution from wild type
and assume that viruses with more than one residue substitution on contact sites are
considered unfit and disappear. If a second residue change occurs outside the contact
site, we assume this has the same fitness as the virus with one contact site residue
change. Based on these criteria, any particular virus in the system can be in one of
three states: wild type, point mutant with known fitness value and mutants with two
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or more mutations. Mutation dynamics are represented by a Markov process.
Let S = {wt,m1, ...,mn, nf, uf} be the state space associated with the Markov
process, corresponding to infected cell types where wt is the wild type infected cell,
m1, ...,mn are point mutant infected cells that produce virus with known fitness, nf is
an infected cell type that produces virus with unknown fitness, and uf is an infected
cell type that produces virus considered unfit. As an approximation, we consider
infected cells that produce mutant virus where no fitness knowledge to be equivalent
in fitness to wild type, and those that produce virus with more than one residue
change are considered unfit. Let Xn be a random variable denoting the state of a
given cell at time n taking values in S, then its dynamics are given by the following
state transition probabilities P = {pij} = P{Xn+1 = j|Xn = i}:
pwt→wt = (1− u)kl
pwt→mi = kcu(1− u)kc−1(1− u)kh
pwt→nf = khu(1− u)kh−1(1− u)kc
pwt→uf = 1− pwt→wt − pwt→mi − pwt→nf
pmi→mi = 1−
∑n
j 6=i pmi→mj − pmi→uf
pmi→mj =
2
3kc
pwt→mi
pmi→uf = pwt→nf ,
(2.10)
for i ∈ {1, ..., n} and j 6= i, and where kl is the length of the entire HIV genome, kc
is the length of the genome for which fitness information exists, nc is the number of
possible point mutants with known fitness information, kh = kl−kc, and u is the rate
of mutation of HIV reverse transcriptase. All other state transition probabilities are
not considered. This Markov process at the single cell level induces a Markov process
at the population level.
2.4.2 Model Implementation and Simulations
Measuring the shape of viral distributions. The Gini coefficient measures
statistical dispersion and is most commonly used as a measure of income inequality
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Figure 2.7: A finite state space Markov model representation of simplified mutation dy-
namics. MUTF is an abstract state that encompasses all point mutations for which fitness
information is known, MUTNF is an abstract state that defines all mutations for which
fitness information is not known. The WT state is a wild type virus state, UNFIT final
state is a state that has no infectivity and is considered unfit with respect to any selective
pressure.
in a population. We use this measure as an approximation to the shape of the virus
distribution at steady state. The Gini coefficient G is calculated as
G =
∑n
i=1
∑n
j=1 |yi−yj |
2n2µ
, (2.11)
where n is the number of all possible point mutations, yi is the percent population
of a point mutation i that occurs at steady state for all simulations and µ is their
mean.
2.4.3 Experimental Methods
Mutagenesis, Virus Production and Cells. Site directed mutagenesis and as-
sembly PCR were used to generate YU2-NL43 Env mutants. YU2-NL43 was modified
using unique restriction sites EcoRI and XhoI. Inserts were generated by PCR using
primers EcoRI-CF (5’-GCCAGCCAGAATTCTGCAACAACTGCTGTTTATCCAT
TTCAG-3’) and XhoI-CR-(5’-GCGTCGACCTCGAGATACTGCTCCCACCCCATC-
3’) and individual sense and antisense mutagenesis primers corresponding to YU2-
NL43 mutants listed in Figure 2.4. Escherichia coli One Shot STBL3 Chemically
Competent cells (Life Technologies) were used to propagate proviral plasmids during
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a 16 hour incubation at 30◦ C. Stocks were prepared using a DNA Midi kit (Zymo Re-
search). All gene constructs were verified by complete sequencing of gp160. Cell-free
virus was produced by transfection of HEK293T cells with YU2-NL43 virus coding
plasmid using BioT (Bioland Scientific). Viral supernatant was harvested at 48 h post
transfection, filtered through a 0.5 µm filter and aliquots were stored at -80◦ C. Stock
concentrations were quantified by p24 enzyme-linked immunosorbent assay (ELISA)
(Cell Biolabs). The YU2 Env/NL43 plasmid was obtained from the Nussenzweig
lab, Rockefeller University. The green fluorescent protein (GFP) reporter T-cell line
GXR-CEM is previously described in [11] was obtained through AIDS Research and
Reference Reagent Program, National Institute of Allergy and Infectious Diseases,
National Institutes of Health.
Protein Expression and Purification. Antibodies were transiently expressed
in HEK293T/17 cells or suspension HEK 293-6E cells (National Research Coun-
cil Biotechnology Research Institute, Montréal, QC, Canada) using 25-kDa linear
polyethylenimine (Polysciences) for transfection. Supernatants were passed over Mab-
Select SuRe protein A resin (GE Healthcare) or Protein G Sepharose 4 Fast Flow (GE
Healthcare) and eluted by using pH 3.0 citrate or glycine buffer, and then immedi-
ately neutralized. Antibodies were further purified by size exclusion chromatography
using a Superdex 200 or 75 10/300 GL column.
In Vitro Replication and Neutralization Assays. To initiate infection for
both replication and neutralization assays, GXR-CEM cells at 4× 105 cells/ml were
infected with 200 ng YU2-NL43 (HIV) virus stock in the absence of antibody and incu-
bated for three days at 37◦ C. Two days after infection, uninfected GXR-CEM cells at
2×105 were pre-treated with 0, 0.02,0.08, 0.4,1.6, 6.4, 20, 80 µg/ml of NIH4546G54W
antibody. Three days after initial infection with cell free virus, the infected GXR-
CEM were washed and added to a final concentration of 1 % GFP-expressing donor
cells to uninfected pre-treated GXR-CEM cells. For the neutralization assay, a con-
stant concentration of antibody was maintained for each sample for three days follow-
ing secondary infection. Infection was determined by measuring GFP reporter gene
expression in the absence of antibodies measured daily for four days following sec-
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ondary infection. Neutralization was determined by measuring the reduction in GFP
reporter gene expression in the presence of antibodies NIH4546G54W for three days.
Flow cytometry data was collected with a MACSQuant flow cytometer and trans-
formed to a python format using the FlowCytometryTools python package (Gore lab,
MIT). An automated gating and analysis software module written in python was
developed to process large sets of flow cytometry data.
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2.5 Appendix
Antibody CVE λ1 λ2 λ3
3BNC117 0.387 5.05 3.25 1.7
3BNC55 0.3 5.05 4.6 0.35
NIH45-46G54W 0.612 1.45 1.45 7.1
45-46m2 0.46 1 4.15 4.85
45-46m7 0.425 2.35 6.4 1.25
VRC01 0.227 2.8 4.15 3.05
VRC03 0.316 30 60 10
VRC02 0.322 2.35 3.7 3.95
VRC-PG04 0.382 3.0 6.0 1.05
VRC-PG04b 0.382 50 40 10
b12 0.127 3.7 5.05 1.25
12A12 0.321 20 80 0
VRC-CH31 0.382 30 50 20
PG16 0.485 2.8 5.95 1.25
10-1074 0.373 1.9 3.25 4.85
10-996 0.486 4 5 1
PGT121 0.478 3.25 3.25 3.5
8ANC195 0.274 3.25 4.6 2.15
2F5 0.132 2.8 5.95 1.25
10E8 0.33 5.05 2.8 2.15
4E10 0.159 1.925 3.35 4.725
Table 2.1: 5-fold cross validation error (CVE), optimal λ1, λ2 and λ3 for satlasso models on
antibody neutralization data.
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Antibody Bound Virus PDB accession
NIH-4546G54W 93TH057 4JKP
NIH-4546 93TH057 3U7Y
VRC-01 93TH057 3NGB
VRC-CH31 93TH057 4LSP
3BNC117 93TH057 4JPV
VRC-PG04 93TH057 3SE9
VRC-03 93TH057 3SE8
PG16 YU2 4DQ0
PGT128 HXB2 3TYG
Table 2.2: Antibody and virus molecular structures and their Protein Data Bank (PDB)
accession numbers.
Ligand Envelope molecule Kd Units Ref
CD4 Core gp120 220 nM [67]
CD4 full length gp120 22 nM [67]
12A12 YU2-gp140 0.3 nM [92]
3BNC60 YU2-gp140 6.81 nM [92]
3BNC117 YU2-gp140 6.54 nM [92]
3BNC55 YU2-gp140 57.8 nM [92]
8ANC195 YU2-gp140 34.3 nM [92]
45-46 YU2-gp140 6.75 nM [92]
VRC01 YU2-gp140 0.4 mM [92]
VRC-CH31 YU2 gp140 37.8 nM [107]
VRC-PG04 KER2018 core 11.9 nM [45]
VRC-03 YU2 gp140 16.1 nM [104]
PG16 V1-V2 complex glycan 1.26 mM [75]
Table 2.3: Ligand dissociation constants used in Equation 2.5.
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Parameter Value Units
λ 105 cells · day−1
dx 0.01 day−1
dy 0.01 day−1
kv 100 day−1
ηCD4 10
5 CD4 molecules per T cell
ηgp120 14 gp120 molecules per virion
τ day
T 313 K
R 1.987 kcal · mol−1· K−1
Table 2.4: HIV evolutionary dynamics parameters and units corresponding to Equation
(2.7) and Hill Equations (2.5).
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Chapter 3
Robust Control of Evolutionary
Dynamics
3.1 Introduction
A challenge inherent to the treatment of certain infectious and non-infectious diseases,
such as HIV or cancer, is the risk that the pathogen or tumor will evolve away
and become resistant to treatment methods that comprise the standard of care [35,
46, 48, 76]. Especially vulnerable to this phenomenon are treatment methods that
involve exposing the disease population (such as viruses or cancer cells) to therapies
targeting specific molecules involved in disease progression for an extended period
of time. While these targeted therapies have the benefit of allowing physicians to
tailor treatments to a patient’s tumor cell population, they nonetheless establish an
environment in which the occurrence of mildly drug resistant pathogens or tumor cells
can develop an evolutionary advantage over those for which the therapy is targeted
[23, 27, 41, 97], leading to so called “treatment-escape”.
The challenge of designing treatment protocols that prevent escape is one that
has been addressed by control theoretic methods. For cancer therapy, results in this
spirit apply methods from optimal and receding horizon control [3, 16], as well as
gain scheduling [2], to synthesize treatment protocols that are robust to parameter
uncertainty, an inherent issue in all biological systems. Zhao et al. [105] present
a static multi-objective optimization formulation to solve the combination therapy
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problem for different initial tumor populations, when the drugs under consideration
have additive, linear effects on cell viability. Proposed combination treatments were
confirmed experimentally for different tumor initial conditions in a murine lymphoma
model [106]. In the context of HIV and antiretroviral therapy, the authors in [25]
propose a discrete time formulation that allows for the design of switching therapy
strategies to delay the emergence of highly resistant mutant viruses. Recent results
in [84] and [8], consider a simplified bilinear model and the optimal control problem
is shown to be convex over a finite horizon for a predefined set of initial states.
This chapter presents three algorithms for the principled design of targeted combi-
nation drug treatment strategies that explicitly account for the evolutionary dynamics
of a generic disease model, where the drugs under consideration are non-interacting
and exhibit independent additive effects. Our first algorithm, introduced in [42], pro-
poses a general iterative method that uses an H∞ robust control approach to design
targeted combination therapy concentrations and is effective in generating robustly
stabilizing controllers. Our second algorithm addresses the lack of scalability symp-
tomatic of semidefinite programming (SDP) formulations and proposes a scalable
solution to the combination therapy problem by reformulating it as a second order
cone program (SOCP), with robustness guarantees addressed by minimization of the
induced L1 norm. We also require that the synthesized controller be not only ro-
bust to unmodeled dynamics, but also exhibit sparse structure and small feedback
gains. This is motivated by the fact that the number of therapies commonly used
in combination to treat a disease is often small while the number of potential usable
therapies is often very large [1]. Targeted therapies such as small molecule drugs or
antibodies exhibit a maximum effective concentration beyond which side effects are
likely to worsen and no additional drug benefits are seen. Our third algorithm solves
the combination therapy problem subject to the same design constraints (sparsity of
the drug combination, maximum dosage and robustness constraints) formulated as
an SOCP while addressing the nonlinear dynamics of individual drugs and of their
combinations. In particular, through the piecewise linearization of individual and
combination drug pharmacodynamics, in conjunction with a branch and bound like
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algorithm for the effective search through these linear pharmacodynamic modes, we
reduce the combination therapy problem to applying the SOCP formulation from [44]
to a set of pharmacodynamic modes.
The chapter is organized as follows: in Section 3.2, we formulate the combination
therapy control problem by introducing the evolutionary dynamics of a generic dis-
ease model with replication and mutation, subject to selective pressure from drugs.
We also give a brief introduction to control of positive systems. Sections 3.3, 3.4
and 3.5 propose respectively, 1) an H∞ robust control approach to design targeted
combination drug treatment strategies, 2) an L1 scalable solution to the combination
therapy problem, and 3) a L1 scalable solution to the combination therapy problem
for a nonlinear pharmacodynamics model. We illustrate the applicability of these
methods to antibody treatment strategies for HIV in Chapter 4.
3.2 Problem Formulation
We begin by fixing notation and introducing a simplified, general evolutionary dy-
namics model that encodes replication, mutation and drug selection. We observe that
there is an inherent feedback structure to the aforementioned dynamics that forces
us to consider structured controller synthesis. By showing that our dynamics are in-
ternally positive, we are able to leverage recent results in control of positive systems,
that allow us to greatly simplify stability analysis and controller optimization with
structure constraints.
3.2.1 Notation
R+ denotes the set of nonnegative real numbers. The inequality X > 0, (X ≥ 0)
means that all elements of the matrix or vector X are positive (nonnegative). X  0
means that X is a symmetric and positive definite matrix. The matrix A ∈ Rn×n is
said to be Hurwitz if all eigenvalues have negative real part. Finally, the matrix is
said to be Metzler if all off-diagonal elements are nonnegative. Define 1n to be the
vector of all ones of dimension n. The induced matrix norm for a matrix M ∈ Rr×m
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is ‖M‖p−ind = supw∈Rm |Mw|p|w|p where |w|p = (|w1|p + ... + |wm|p)1/p. Let G(s) =
C(sI − A)−1B + D be a r ×m matrix transfer function. The induced norms of the
corresponding impulse response g(t) = CeAtB +Dδ(t) are ‖g‖p−ind = supw ‖g∗w‖p‖w‖p for
w ∈ Lpm[0,∞), given that g ∗ w ∈ Lrp[0,∞) is the convolution of g and w. Finally we
refer to the ∞-induced robust controller as the L1 controller as is customary in the
robust control literature [19].
3.2.2 Evolutionary dynamics model
The quasispecies model [26] was originally developed to describe the dynamics of
populations of self replicating macromolecules undergoing mutation and selection.
We choose this model for its relative simplicity and its ability to capture the salient
features of the evolutionary dynamics of a simplified generic disease model. In this
thesis, we incorporate the effects of potential therapies into the basic quasispecies
model, by defining a drug binding reaction, ` + ρ KA−−→ ` · ρ - drug ` binds to self
replicating macromolecule ρ with association rate KA, giving a neutralized complex
` · ρ. The extended quasispecies model for n mutants and m drugs, is written as
x˙i = (riqii − di)xi +
n∑
k 6=i
riqikxk − ψi(`)xi, (3.1)
where xi ∈ R+ is the concentration of mutant i, ` = (`k) ∈ Rm+ is the drug concen-
tration (assumed to remain at constant concentrations throughout), ri and di are the
replication and degradation rates, respectively, of mutant i, and qik is the probability
that mutant k mutates to mutant i (note that qii is the probability of no mutation
occurring). The rates ri can be viewed as the replication fitnesses of mutant i with-
out the effect of the drug. When `k = 0, for all k ∈ {1, ...,m}, the quasispecies
dynamics are unstable. Finally, the function ψi(`) represents the pharmacodynamics
of individual drugs `k and their combinations with respect to the i-th mutant species.
The map ψi(`) is a function defined as the sum of nonlinear functions representing
additive drug effects, represented by Hill equations and described in the next section.
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3.2.3 The Hill equation
The Hill equation has been used in pharmacology to model nonlinear drug dose-
responses, such as the concentration dependent effects of drugs on cell viability or
virus neutralization. More generally it serves to quantify drug-receptor relationships,
the fraction of bound receptors ρ (e.g. cell receptors, virus proteins) as a function of
ligand `k (e.g. drug, antibody) concentrations for the binding reaction
`k + ρ
KA−−→ `k · ρ,
ψρ(`k) =
[`k]
nk
[`k]
nk+K
nk
k
,
(3.2)
where ψρ(`k) ∈ [0, 1] is the fraction of bound receptors, `k ∈ R+ is the concentration
of ligands, Kk = 1KA ∈ R+ is the dissociation constant associated with the binding
reaction (3.14), nk ∈ R+ is the Hill coefficient that represents the degree of coopera-
tivity, i.e. the degree to which binding of a ligand molecule modulates the probability
of another ligand molecule binding.
We notice that the Hill function is a biological analog to actuator saturation, in
that there is a law of diminishing returns in terms of the effect of ever increasing drug
concentrations on the system. In particular, the Hill functions ψρ(`k) that appear in
most pharmacodynamic models look approximately linear for small to moderate `k,
and nearly constant for large `k. The application of algorithms developed in previous
Sections 3.3 and 3.4 assume that the Hill equation can be approximated by a linear
function and inequality constraints. In Section 3.5, we provide a finer approximation
of the Hill function by using piecewise linear approximations to solve the combination
therapy problem subject to nonlinear pharmacodynamics. For all algorithms devel-
oped in this chapter, we consider combinations of independently acting drugs that
exhibit an additive effect.
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3.2.4 State space representation
The following state space representation of equation (4.6) emphasizes the inherent
feedback structure that arises from drug binding reactions:
x˙ = (A−Ψ(`))x+ w
z = Cx
(3.3)
with A ∈ Rn×n, with Aij = riqij ≥ 0 ∀ i 6= j and Aii = riqii − di, that encodes the
mutation and replication dynamics; Ψ(`) ∈ Rn×n, a diagonal matrix, with diagonal
elements ψi(`) representing additive drug effects for each mutant i; ` = (`k) ∈ Rm, a
vector of individual drug concentrations; C = 1Tn ∈ R1×n; and w ∈ Rn+ an arbitrary
positive disturbance. We set the regulated output z = 1Tnx to be the total mutant
population, so as to ensure that the resulting treatment plan is one that robustly
drives the total mutant population to zero.
If we approximate drug effects for each mutant ψi(`) be a linear function of `,
then we can construct an appropriately defined block diagonal matrix Ψ such that
Ψ(`) = ΨL where L = I⊗ ` ∈ Rmn×n. In this particular case, the closed loop transfer
function from input to output system is given by
G(s) = C(sI − (A−ΨL)−1B +D. (3.4)
The control task then becomes to engineer drug concentrations ` by finding a “con-
troller” L = I ⊗ ` ∈ Rmn×n that leads to a stable G satisfying ||G||∞−ind < γ, for
some desired robustness level γ > 0.
3.2.5 Control of positive systems
Recent results on the synthesis of controllers for positive systems show that the design
of structured static state feedback controllers for internally positive systems can be
reformulated as a convex problem with methods that scale linearly with the number
of non zero elements in the feedback matrix [82, 83].
41
Briefly, we recall definitions from positive systems theory [96]. We will then expand
the background on control of positive systems as needed in Section 3.3.1 and Section
3.4.1.
Definition 2. The LTI system
x˙ = Ax+Bw
z = Cx+Dw
(3.5)
with A ∈ Rn×n, B ∈ Rn×q, C ∈ Rp×n and D ∈ Rp×q is called internally positive if
for every x0 ∈ Rn+ and all inputs such that w(t) ∈ Rq+ for all t ≥ 0, the state vector
x(t) belongs to Rn+ and the output vector z(t) belongs to R
p
+ for all t ≥ 0.
The internal positivity of a system is easily determined by a simple condition on
its system matrices:
Lemma 3. System (3.5) is internally positive if and only if
1. A is Metzler, and
2. B,C,D ≥ 0, i.e. matrices B, C, and D are entry-wise non-negative.
We observe that in the state space system (3.3), A is a Metzler matrix with
off-diagonal entries that are several orders of magnitude smaller than the diagonal
entries. This is due to the biological fact that mutation rates range from 10−5 - 10−8
mutations per base pair per replication cycle for reverse transcriptase [58] to DNA
replication [68].
In light of this result, it is straightforward to show that system (3.3) is internally
positive:
Lemma 4. System (3.3) is internally positive.
Proof. Condition 2) of Lemma 3 is easily seen to be satisfied by noting that in equa-
tion (3.3), B = I, C = 1T and D = 0. To see that A − Ψ(`) is Metzler, it suffices
to notice that since Ψ(`) is strictly diagonal, it cannot affect the Metzler property of
A.
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3.3 Static state feedback strategies for combination
therapy using H∞ control
We introduce a general algorithm for the systematic design of feedback strategies
to stabilize the evolutionary dynamics of a generic disease model using an H∞ ap-
proach. We show that designing therapy concentrations can be cast as an H∞ state
feedback synthesis problem, where the feedback gain is constrained to not only be
strictly diagonal, but also that its diagonal elements satisfy an overdetermined set of
linear equations. Leveraging recent results in positive systems [82, 96], we develop an
algorithm that always yields a stabilizing controller.
We recall recent results on the synthesis of structured static state feedback con-
trollers for positive systems in Section 3.3.1, and propose an algorithm to solve for a
stabilizing H∞ sub optimal controller in Section 3.3.3.
3.3.1 The bounded real lemma for internally positive systems
Recent results by Tanaka and Langbort [96] and Rantzer [82] on the synthesis of
H∞ controllers for positive systems show that the design of structured static state
feedback controllers for internally positive systems can be reformulated as a convex
problem. In this section we provide a brief survey of the relevant definitions and
results from [96].
In Section 3.2.5, we showed that our system (3.3) is internally positive. Systems
that are internally positive enjoy the significant advantage that the storage function
matrix used in the bounded real lemma to characterize the H∞ norm of a system via
a semi-definite program (SDP), can be taken without loss to be diagonal, as outlined
in the following theorem, slightly modifed from [96].
Theorem 5. Let the system (3.5) be internally positive with (A,B) stabilizable and
(C,A) detectable. Let the corresponding transfer function be given by G(s) := C(sI−
A)−1B +D. Then the following statements are equivalent:
1. ‖G‖∞ < γ and A is Hurwitz;
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2. There exists a diagonal matrix X > 0 such that ATX +XA+ CTC XB + CTD
BTX +DTC DTD − γ2I
 ≺ 0. (3.6)
The fact that X can be restricted to be diagonal is very useful in synthesizing
structured feedback controllers, when this structure is defined by sparsity in the feed-
back gain. Our setting, however, requires not only sparsity, but a type of algebraic
consistency — the controller structure L = I ⊗ ` implies that each block diagonal
element of L must be equal. Unfortunately, there is no known way of enforcing this
additional coupling in a convex manner.
In the following sections, we deal with the aforementioned non-convexity of the
optimal control problem by formulating an iterative algorithm for finding effective
drug concentrations, exploiting the internal positivity of the system to show that it
always yields a stabilizing controller.
3.3.2 Initializing stabilizing controller
We begin by synthesizing a stabilizing controller to use as an initial controller in our
iterative algorithm, as noted, which admits a particularly simple formulation in light
of the Metzler nature of A and the diagonal structure of ΨL.
Lemma 6. There exists  > 0 such that the solution to the convex program
minimize `∈Rm+ ||`||∞
subject to
Ad + I −ΨL ≺ 0
L = I ⊗ `
(3.7)
is a stabilizing controller for system (3.3), where Ad is a diagonal matrix comprised
of the diagonal elements of A.
Proof. Rewrite A = Ad + M where Ad is diagonal and M = {mij} ∈ Rn×n, mij =
0 for i = j and mij > 0 for i 6= j. By the Perron-Frobenius theorem, there exists
r > 0 such that the spectral radius ρ(M) = r ≤ maxi
∑
mij. Let  = maxi
∑
mij
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and rewrite M = I − (I −M). We note that −(I −M) ≺ 0. The closed loop
dynamics are then given by A−ΨL = Ad + I − (I −M)−ΨL ≺ Ad + I −ΨL ≺ 0,
yielding the desired stability.
Remark 7. The stabilization problem can be solved independently of a storage func-
tion because it can be reduced to satisfying element wise inequalities.
3.3.3 An H∞ combination therapy controller
Observe that through a straightforward application of inequality (3.6) to system (3.3),
the antibody concentrations ` yielding an optimal H∞ closed loop norm can be found
by solving the following non-convex program:
minimize γ
subject to ATclX +XAcl + (ΨL)T (ΨL) X
X −γ2I
 ≺ 0
Acl = (A−ΨL)
L = I ⊗ `
X  0, X diagonal
(3.8)
Applying a Schur complement to ATclX + XAcl + (ΨL)T (ΨL) yields the more
amenable form
minimize γ
subject to
ATclX +XAcl X (ΨL)
T
X −γI 0
ΨL 0 −γI
 ≺ 0
Acl = (A−ΨL)
X  0, X diagonal
(3.9)
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Remark 8. We can impose an additional constraint limiting the concentrations of can-
didate therapies. This is necessary with certain drugs that have maximum tolerated
doses dictated by clinical trials.
Thus the only non-convexity remaining are the product terms between the storage
function matrix X and the controller gain ` in ATclX + XAcl. As mentioned earlier,
there are no known convex reformulations of this problem due to the additional struc-
ture on `. As such, we suggest the following iterative algorithm, based on the convex
programs (3.7) and (3.9), to find a stabilizing controller.
For ease of notation, let PX′(`, γ) denote that we solve (3.9) with X = X ′ fixed,
and that we optimize over ` and γ. Similarly, let P`′(X, γ) denote that we solve (3.9)
with ` = `′ fixed, and that we optimize over X and γ. Additionally, let (Z, γ) =
PZ′(Z, γ) denote the solutions to the respective programs, for Z,Z ′ ∈ {X, `}. We are
now in a position to present our algorithm:
Algorithm 1 H∞ Combination Therapy
1. Set  > 0
2. Solve (3.7) to obtain an initial stabilizing controller `′.
3. while γ′ − γ >  :
(a) Set (X ′, γ) = P`′(X, γ).
(b) Set (`′, γ) = PX′(`, γ).
(c) Set γ′ = γ.
Proposition 9. Algorithm 1 always converges to a feasible γ and generates a stabi-
lizing controller for (3.3).
Proof. By Lemma 6, an initial stabilizing controller can always be found, and thus the
algorithm can always be initialized. The sequence of γs then defined by the iterative
process in Algorithm 1 is non-increasing by construction, and bounded below by 0,
thus implying convergence. We therefore have that our algorithm always converges
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to a local minimum value of γ, and yields a set of gains which, by the bounded real
lemma, robustly stabilizes system (3.3).
3.4 Static state feedback strategies for combination
therapy for large-scale systems
In Section 3.3, we introduced a general algorithm that used an H∞ approach for the
principled design of targeted combination therapy concentrations that explicitly ac-
count for the evolutionary dynamics of a generic disease model. This algorithm was
effective in generating robustly stabilizing controllers, however it suffered from an
inherent lack of scalability symptomatic of semidefinite programming formulations.
Here,we propose a scalable solution to the combination therapy problem by refor-
mulating it as a second order cone program (SOCP). We simultaneously address the
requirement that the synthesized controller be not only robust to unmodeled dynam-
ics but also exhibit sparse structure and small feedback gains, and allow the designer
to explore respective tradeoffs. In particular, through `1 and `2 regularization, we in-
duce sparse structure in the feedback controller while bounding the magnitude of the
feedback gains, leading to a SOCP formulation of the combination therapy synthesis
problem. In this section, we propose a scalable algorithm for the systematic design
of sparse, small gain feedback strategies to stabilize the evolutionary dynamics of a
generic disease model.
3.4.1 Controller synthesis by linear programming
In this section, we provide a brief survey of the relevant definitions and results from
design of structured static state feedback controllers for positive systems, [83].
Theorem 10. For the system
x˙ = (A+ ELF )x+Bw
z = (C +GLF )x+Dw
(3.10)
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let D be the set of m×m diagonal matrices with entries in [0,1]. Suppose that A+ELF
is Metzler and C +GLF ≥ 0 for all L ∈ D. Let g(t) be the impulse response of
G(s) = (C +GLF )[sI − (A+ ELF )]−1B +D
If the matrices B,D and F have non-negative coefficients, then the following two
conditions are equivalent:
1. There exists an L ∈ D with A+ ELF Hurwitz and ‖g‖∞−ind < γ.
2. There exists a ξ ∈ Rn+, µ ∈ Rm+ with
Aξ + Eµ+B1 < 0
Cξ +Gµ+D1 < γ1
µ ≤ Fξ
If ξ, µ satisfy the linear constraints 2) then the stability and norm guarantees of 1)
hold for every L such that µ = LFξ.
Input-output performance is characterized using induced norms, which are deter-
mined by the closed loop system’s static gain:
Theorem 11. For an r ×m transfer matrix G(s) = C(sI − A)−1B + D, let g(t) =
CeAtB + Dδ(t) be the corresponding impulse response, where CeAtB ≥ 0 for t ≥ 0
and D ≥ 0, with A Hurwitz. Then ‖g‖p−ind = ‖G(0)‖p−ind for p = 1, p = 2 and
p =∞.
The positive nature of the system allows us to restrict ourselves to linear storage
functions, which in turn allows for sparse structure to be imposed on the feedback
gain [82]. Our feedback gain L = I ⊗ ` is not only structurally constrained to be
block diagonal, but algebraically constrained as well, in that all block diagonal com-
ponents must be equal. Unfortunately, there is no known convex reformulation for
this additional constraint.
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3.4.2 Regularization for structured controller synthesis
The biomedical justification for wanting a simple controller structure with small gains
is twofold: first, the number of therapies that can be used simultaneously to treat
a disease is often limited, and second to minimize side effects, it is desirable to
keep the magnitude of drug concentrations small while being robust to pharmaco-
dynamic perturbations. These design specifications can be expressed with the use of
regularization, a common technique used in machine learning and inverse problems
for model identification [13, 24, 85, 15] and increasingly used for controller design
[60, 53, 21, 28, 59]. As such, we introduce `1 and `2 penalties in our design objective
to promote controller sparsity and minimize controller gains.
We combine these regularization techniques with controller synthesis results for
positive systems and present an iterative algorithm that yields a suboptimal L1 con-
troller. This formulation of the combination therapy problem allows the designer
to explore explicit trade offs between closed loop performance, sparsity in controller
structure and gain minimization.
In the following sections, we address the aforementioned non-convexity of the
optimal control problem by formulating an iterative algorithm for finding effective
drug concentrations. Our main result addresses the issue of synthesizing a stabilizing
controller subject to the constraints imposed by the quasispecies model (3.3), with
acceptable robustness properties characterized in terms of its ∞-induced closed loop
norm.
3.4.3 A scalable L1 combination therapy controller
Observe that through a straightforward application of Theorem 11, with B = I, C =
1T , D = 0, E = −Ψ, F = I to system (4.6), solving the following non-convex
program:
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minimize
`∈Rm+ ,x∈Rn+
‖Cx‖∞ + λ1‖`‖1 + λ2‖`‖2
subject to
Ax+Kx+ 1 ≤ 0
K = ΨL
L = I ⊗ `
x ≥ 0
(3.11)
will yield a sparse combination of drug concentrations `, yielding an optimal ∞-
induced closed loop norm for appropriately chosen regularizers λ1 ≥ 0, λ2 ≥ 0 ∈ R.
Remark 12. We can impose an additional constraint limiting the concentrations of
candidate therapies. This is necessary with certain drugs that have maximum toler-
ated doses dictated by clinical trials.
As mentioned earlier, there are no known convex reformulations of this problem
due to the additional structure on L. As such, we suggest the following iterative
algorithm, based on the convex programs (3.9) and (3.23), to find a stabilizing con-
troller. For notation, let Y = PZ(x, γ) denote an optimization problem P in which
we optimize over x and γ leaving Z fixed and with solution Y .
Program 1. P1`(x, γ) :
minimize
γ,x∈Rn+
γ
subject to
Ax+ ΨLx+ 1 ≤ 0
L = I ⊗ `, C = 1T
x ≥ 0
γ ≥ ‖Cx‖∞
(3.12)
Program 2. P2(x,λ1,λ2)(`, γ)
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minimize
γ,`∈Rm+
γ + λ1‖`‖1 + λ2‖`‖2
subject to
Ax+ ΨLx+ 1 < 0
L = I ⊗ `, C = 1T
γ ≥ ‖Cx‖∞
(3.13)
We now present our algorithm:
Algorithm 2 Scalable Combination Therapy
1. Set  > 0.
2. Solve for initial stabilizing controller `′:
Solve convex program (3.7) to obtain controller `0.
Set (x′, γ) = P1`0(x, γ).
Set (`′, γ) = P2(x′,0,0)(`, γ).
3. Find (λ′1, λ′2, `) that minimize γ:
∀(λ1, λ2) ∈ Λ1 × Λ2,Λ1,Λ2 ∈ Rk+,
while γ′ − γ >  :
Set (x′, γ) = P1`′(x, γ).
Set (`′, γ) = P2(x′,λ1,λ2)(`, γ).
Set γ′ = γ.
Remark 13. The sequence of γ’s defined by the iterative process in Algorithm 1 is non increasing by construction, and bounded below by 0, thus implying convergence. An initial stabilizing controller can always be found as shown in ??, and thus the algorithm can always be initialized. We therefore have that our algorithm always converges to a feasible, local minimum robustness value γ, generating a stabilizing controller for (2).
Remark 14. In practice, we note that the L1 controller suffers from dependence on ini-
tial conditions and converges to local optima quickly, yielding a stabilizing controller
with robustness properties that are not significantly different from the nominal con-
troller. A solution to this is to iterate once through P1 and P2, with λ1 = λ2 = 0
and initialize the algorithm with the resulting controller.
Remark 15. Due to the presence of the `2 regularizer, P2 and (5) are SOCPs and
not linear programs. As it will be clearly demonstrated in an example in the next
chapter, this is still more efficient than the SDP combination therapy algorithm from
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Section 3.3.3 [42]. In addition, the second order cone constraint is only on the drug
concentrations so has a minimal effect on performance [].
3.5 Feedback strategies for combination therapy for
large scale systems with nonlinear pharmacody-
namics
In Section 3.4, we introduced a scalable, iterative algorithm for the principled de-
sign of targeted combination therapy concentrations that explicitly accounts for the
evolutionary dynamics of a generic disease model. This algorithm was effective in
generating robustly stabilizing controllers, while simultaneously allowing the designer
to explore explicit trade offs between closed loop performance, sparsity in controller
structure and gain minimization. Leveraging recent results from positive systems
[83], we formulated this algorithm as a second order cone program (SOCP), which
made the controller synthesis scalable. However it could not take into account a) the
pharmacodynamics of the input, potentially suffering from over or underestimating
gains, and b) the effects of synergistic or antagonistic drug combinations that can be
modeled with additional nonlinear pharmacodynamic terms [102].
In this section, we propose an algorithm that solves the combination therapy prob-
lem subject to the same design constraints (sparsity of the drug combination, max-
imum dosage and robustness constraints) formulated as an SOCP while addressing
the nonlinear dynamics of individual drugs and of their combinations. In particular,
through the piecewise linearization of individual and combination drug pharmacody-
namics, in conjunction with a branch and bound like algorithm for the effective search
through these linear pharmacodynamic modes, we reduce the combination therapy
problem to applying the SOCP formulation from [44] to a set of pharmacodynamic
modes.
The main contribution of this section is an algorithm for the systematic design
of sparse, small gain feedback strategies to stabilize the evolutionary dynamics of a
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generic disease model and general nonlinear pharmacodynamics models, which sup-
port synthesis of feedback strategies in light of highly nonlinear drug dynamics.
3.5.1 Pharmacodynamic models
Pharmacodynamic models are used to quantitatively describe nonlinear drug dose-
responses and model drug-receptor relationships. These models are often described
using combinations of nonlinear Hill functions, and allow for the modeling of drug
saturation effects [86, 90, 78]. These pharmacodynamic nonlinearities are further in-
creased with the fact that drugs administered in combination can have independent
additive effects or can otherwise exhibit synergistic or antagonistic dose dependent
behavior, further complicating the design of suitable combination therapies [102].
There have been several attempts to deal with nonlinear HIV infection dynamics
using model predictive control (MPC) to design optimal antiretroviral drug dosing
strategies [56, 108]. With MPC and other linear control synthesis methods, an es-
sential feature of the system, that of nonlinearities associated with drug binding, is
linearized away. In particular, such an approach can lead to a model that underesti-
mates the efficacy of a drug at lower concentrations, and over estimates its efficacy at
high dosages unless a sufficiently small update time is taken. This latter restriction
may then lead to strategies that are no longer realistic in a biomedical application,
where it may be difficult to update the administered therapies at the frequency dic-
tated by the MPC controller. In this section, we take an alternative approach and
attempt to design constant drug therapies by taking input nonlinearities into account
more explicitly. In particular, through the piecewise linearization of individual and
combination drug pharmacodynamics, in conjunction with a branch and bound like
algorithm for the effective search through these linear pharmacodynamic modes, we
reduce the combination therapy problem to applying the SOCP formulation from [44]
to a set of pharmacodynamic modes.
When combined, drugs can have additive, synergistic or antagonistic effects that
need to be explicitly accounted for when designing combination therapies. When the
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presence of one drug modulates the effect of another, the combined drug effects are
no longer additive, and in particular, the phamacodynamics of the drug interaction
now incorporate additional terms that represent this interaction.
We use the Hill equation introduced in Section 3.2.3 to model the nonlinear phar-
macodynamics of independently acting drugs, in which the effect of each drug on
the system is additive. Consider the system of m drug binding reactions to different
receptors on a particular cell or virus x:
`1 + ρ1
K1←− `1 · ρ1, ..., `m + ρm Km←−− `m · ρm (3.14)
where `k is the drug k and ρk is a receptor. If these receptors comprise different drug
binding targets on a cell or virus x, then we can describe the total effect of these
independently acting drugs `1, ..., `m on x as
Ψx(`) =
∑m
k=1 ψρk(`k). (3.15)
Remark 16. Although we focus on this drug interaction model, we note that our
approach applies nearly verbatim to a synergistic/antagonistic drug binding model
– it suffices to use a suitable expression for Ψx(`) to take these interactions into
account. We do note however that this may lead to a more involved piecewise linear
approximation procedure.
In the following sections, we formulate the task of designing suitable combination
therapies as an optimal control problem. The inherent nonlinearities of the system
make this a challenging task — in [42, 44], we worked with a simplified problem in
which we assumed the Ψx(`) were linear functions – in this section we relax that
assumption, and show that at the expense of some additional modeling complexity,
we are able to reduce the problem to that considered in [44]. Our main result is based
around the use of piecewise linear approximations, and relating the robustness levels
of the approximate system to that of the true underlying system.
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3.5.2 Piecewise linear mode approximations and mode reduc-
tion
In the following sections, we assume that each (Ψ(`))ii = Ψxi(`) has the form given
by Equation (3.14). To take into account nonlinear pharmacodynamics, we pro-
pose a piecewise linear approximation algorithm and a mode reduction algorithm
for problems where there is a large number of non interacting or synergistic drug
combinations.
We assume that the pharmacodynamics for every individual drug and combination
are defined over the same drug concentration domain D ∈ R. Let P = {p1, ..., pk} be
a partitioning of this domain into k intervals.
Definition 17. A pharmacodynamic mode ω = (ω1, ..., ωm) is an m-tuple in Pm.
The total number of pharmacodynamic modes is |P|m where m is the number of drugs
under consideration. For ` ∈ Rm, we define ` ∈ ω ⇐⇒ `i ∈ ωi, for all i =
{1, 2, ...,m}.
We let ψiω : Rm → R be the affine approximation of the pharmacodynamics for
each mutant i for ` ∈ ω, i.e. the sum of the individual and combination drug effects
on mutant i while operating within mode ω. We can then construct a linear approx-
imation to Ψ(`) via an appropriately defined block diagonal matrix Ψω, constructed
from the ψiω (c.f. [44]), and write Ψ(`) = ΨωLω, where Lω = (I ⊗ `ω) ∈ Rmn×n+ is
the block diagonal matrix, with identical block diagonal elements given by the drug
concentrations ` ∈ ω. The resulting dynamics, for a fixed concentration ` ∈ ω, are
then described by the transfer function
G`ω(s) = C(sI − (A−ΨωLω)−1B +D. (3.16)
We consider the problem of finding a suitably sparse therapy combination that
achieves a certain closed loop performance level γ. As such, our initial goal becomes
to reduce the search space to the set of sparse modes that achieve the desired level of
robustness, where a sparse mode ω is one that allows at least one drug concentration
55
to be zero, in other words, 0 ∈ ωi for at least one ωi ∈ ω.
In order to do so, we require two lemmas. The first provides sufficient condi-
tions on the linear approximation terms ψiw that guarantee that the robustness of
the piecewise linear approximation is an upper bound on that of the true system.
The second is the simple observation that for non-interacting or synergistic additive
drug interactions, the robustness of the closed loop dynamics increases as drug con-
centrations are uniformly increased (this statement will be made precise). This result
allows us to subsequently develop a branch and bound like method that significantly
reduces the search space of the algorithm.
We begin with a result on the input-output performance of a positive system,
taken from [83].
Lemma 18. Let G(s) = C(sI−A)−1B+D be a positive system. Then ‖G‖∞−ind ≤ γ
if and only if there exits x ≥ 0 such that
Ax+B1n < 0
Cx ≤ γ
(3.17)
Lemma 19. Let Ψ(`) be the nonlinear pharmacodynamics function, ψ(`) the vector of
its diagonal elements, and denote by Ψω(`) its piecewise linear approximation within
mode ω, and by ψω(`) the vector of its diagonal elements. If for every mode ω we have
ψω(`) ≤ ψ(`) for all ` ∈ ω then the L1 norm γ of the piecewise linear approximation
(3.16) is an upper bound on that of the true system (3.3).
Proof. Note that for a fixed `, both the full and piecewise linear approximation sys-
tems are linear in x. Therefore, by Lemma 18, the L1 norm of (3.16) is upper bounded
by γ if and only if there exists an x > 0 such that
(A−Ψω(`))x+ 1n < 0
1Tnx ≤ γ
(3.18)
Thus it suffices to show that this same x yields (A−Ψ(`))x+1n ≤ 0 and the desired
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conclusion follows immediately. To that end, rewrite the first inequality of (3.18) as
(A−Ψ(`))x+ 1n < (Ψω(`)−Ψ(`))x, (3.19)
and notice that the right hand side is less than or equal to 0 by the assumptions of
the lemma.
This lemma essentially states that if our piecewise linear approximation is conser-
vative, then the norm of the approximate system serves as a certificate for the norm
of the true system.
Next we formalize the observation that increasing the concentrations of non or
synergistically interacting therapies present in the system will improve robustness.
Lemma 20. Let `1 and `2 be therapy combinations such that `1 ≥ `2. Then if the
piecewise linear approximation Ψω(`) is non-decreasing, ||G1||∞−ind ≤ ||G2||∞−ind,
where
Gi = C(sI − (A−Ψω(`i))−1I.
Proof. By assumption, the piecewise linear function Ψω(`) is non-decreasing. Thus if
`1 ≥ `2, then Ψω(`1) ≥ Ψω(`2). Let γi = ||Gi||∞−ind. By Lemma 18, γi is the solution
to the following optimization:
minimize
γ,x≥0
γ
subject to
(A−Ψω(`))x+ 1 < 0
Cx ≤ γ
(3.20)
Let γ2 and x be the optimal solutions of the above program for i = 2. Then we
have that
(A−Ψω(`1))x+ 1 ≤ (A−Ψω(`2))x+ 1 ≤ 0. (3.21)
Hence (γ2, x) is a feasible solution for optimization (3.20) with i = 1, implying that
γ1 ≤ γ2.
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Thus we see that by constraining the piecewise linear approximations to be under
approximations of the effects of the drugs, we are able to bound the performance of
the true system.
Remark 21. We note that these results typically will not hold for antagonistic drug
interactions — however, many settings in which such models are required (such as
cancer therapy design) do not have a large set of therapies or mutants, thus mitigating
the computational cost of the sequential search across modes.
We exploit this result to reduce the modes that need to be searched over — in
particular, we use the partial order implied by the previous two results to upper and
lower bound the uniform concentration treatments required to achieve a prescribed
performance level γ. We also exploit the fact that we are searching for sparse treat-
ment strategies to further eliminate modes.
This approach is formalized in the following algorithm. Let `ωmax ∈ Rm, be the
maximum possible drug concentrations.
Algorithm 3 Sparse mode reduction algorithm
Set `ωi ← `ωmax , γ > 0.
while ¬(`ωi == 0n ∧ ) :
if ||G`ωi || < γ,
S = S ∪ ωi
else
U = U ∪ ωi.
Set `ωi+1 =
`ωi
2
.
Set  = (ωi ∈ S || ωi ∈ U)
The sparse mode reduction algorithm will generate a set of modes that are guar-
anteed to be stable and achieve a desired robustness level γ, and “sparse”, i.e. allowing
modes such that at least one drug concentration is allowed to be zero, significantly
reducing the number of the modes over which to apply the combination therapy
algorithm. In the example described in Chapter 4, we synthesize controllers with
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robustness level γ = 14. We start with |P|m = 10000 possible modes to search over,
and reduce this number to 397 sparse modes.
3.5.3 A static state feedback combination therapy algorithm
for nonlinear pharmacodynamics
As discussed in [42, 44] there are no known convex reformulations for the robust
combination therapy problem due to the additional structure on L. As such we use
the iterative approach developed in [44], as formalized in the previous section, based
on the convex programs (3.12) and (3.13), to find a stabilizing controller, given a
desired robustness level γ. For notation, let Y ′ = PZ′(x, s) denote an optimization
problem P in which we optimize over x and s leaving Z ′ fixed and with solution
Y ′. These optimization programs, taken from [83], are a synthesis variant of the
conditions stated in Lemma 18.
Program 1. P1`,ω(x, s) :
minimize
x∈Rn+,s
s
subject to
Aωx+ ΨωLx+ 1 ≤ s
L = I ⊗ `, ` ∈ ω
1Tnx ≤ γ
s < 0, x ≥ 0
(3.22)
Program 2. P2(x,λ1,λ2,ω)(`)
minimize
`∈Rm+
λ1‖`‖1 + λ2‖`‖2
subject to
Aωx+ ΨωLx+ 1 < 0
L = I ⊗ `, ` ∈ ω
1Tnx ≤ γ
(3.23)
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Algorithm 4 Scalable Combination Therapy For Nonlinear Pharmacodynamics
1. Set `0 = `ωmax .
2. Check if P1`0,ω(x, s) is feasible. If feasible
Set (x′, s′) = P1`0,ω(x, s).
Set (`′) = P2(x′,0,0,ω)(`).
else, move to next mode and return to Step 1.
3. Find (λ′1, λ′2, `ω) for mode ω:
∀(λ1, λ2) ∈ Λ1 × Λ2,Λ1,Λ2 ∈ Rk+,
Set s = 1.
while ¬(s′ == s) :
Set s = s′.
Set (x′, s′) = P1`′,ω(x, s).
Set (`′) = P2(x′,λ1,λ2,ω)(`).
Remark 22. Note the introduction of a slack variable s into Program 1, to help
prevent immediate convergence to a local minimum. Minimizing s has the effect of
maximizing the slack in the first constraint, allowing for more freedom in the design
of the concentration vector ` in Program 2.
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Chapter 4
Engineering Antibody Treatment
Strategies to Control HIV
4.1 Introduction
A relatively recent discovery is that a minority of HIV-infected individuals can pro-
duce broadly neutralizing antibodies (bNAbs), that is, antibodies that inhibit infec-
tion by many strains of HIV [52]. These have been shown to inhibit infection by a
broad range of viral isolates in vitro but also protect non-human primates against
infection [5, 22, 52]. Passive transfer of human antibodies for the prevention and
treatment of HIV-1 infection is increasingly being considered as an alternative to a
conventional vaccine [14]. Only the most potent bNAbs are likely to be successful
therapeutics, thus it is desirable from efficacy and monetary perspectives to deliver the
best bNAb combinations. These bNAb combination treatment strategies aim to re-
produce the success that resulted in combining antiretroviral drugs for the treatment
of chronic HIV infection, and in addition have the potential of offering complete,
long term viraemic control by enhancing host immunity [10, 69]. However, as the
number of potential bNAbs grows, experimentally screening their combinations and
concentrations for effectively controlling the evolution of HIV becomes increasingly
infeasible. To address this, we require a scalable methodology that can take into
account increasing amounts of HIV/bNAb resistance data, bNAb pharmacodynamic
models and HIV mutational dynamics.
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In Sections 3.4 and 3.5, we proposed a new scalable and computationally tractable
algorithm that solves for optimal combinations and concentrations of bNAbs to neu-
tralize virus in light of viral evolution while simultaneously allowing the designer to
tailor treatment strategies in light of viral composition, maximum achievable doses,
number of bNAbs used and ability to support pharmacodynamics/pharmacokinetic
fluctuations, modeling and experimental error [43, 44]. Preliminary in vitro exper-
imental data shows that our combination therapy algorithm predicts combinations
and concentrations of bNAbs that can neutralize heterogeneous viral populations in-
cluding those that include resistant mutants for one or more in the antibody mix
(Figure 4.5).
The chapter is organized as follows: in Section 4.2, we demonstrate our ability to
model control of the evolution to resistance of HIV in the presence of antibody therapy,
through the application of the combination therapy algorithms developed in Chapter
3 as applied to experimental data derived from recent published studies [14, 22, 47].
We compare the H∞ and the L1 combination therapy algorithms from Sections 3.3.3
and 3.4 with respect to their performance and robustness to biologically relevant
uncertainty models and unmodeled dynamics. In Section 4.3, we discuss preliminary
in vitro experimental methodology and results and show that the antibody treatment
strategies synthesized with the nonlinear pharmacodynamics combination therapy
algorithm described in Section 3.5.3 controls infection despite the presence of a mixed
initial population of viruses, most of which are resistant to at least one antibody in
the mix.
4.2 Mathematical Simulations
4.2.1 Model parameters
We consider a system of twenty eight HIV mutations with five potential antibodies
to use in combination. Table 4.4 lists the mutations that evolved from monotherapy
experiments with their corresponding half maximal inhibitory antibody concentra-
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tion (IC50) in µg/ml, as measured in [47]. Antibodies 3BC176, PG16, 45-46G54W,
PGT128 and 10-1074 are potential combination therapy candidates.
Infected cell replication rates. Although virus replication rates can vary con-
siderably depending on the nature of the mutations a virus may undergo, we choose
replication rates to be 0.5 (ml·day)−1 for all mutants. We justify this selection by not-
ing that escape mutants grew to be dominant mutants during selection experiments
in [47] and assume that replication rate variability due to mutations were negligible.
Neutralization parameters. The fitness function associated with the neutral-
ization of a virus i with respect to an antibody j is a Hill function
ψij =
`nj
`nj +K
n
ij
, (4.1)
where n is the Hill coefficient, `j is the concentration of a given antibody j,
Kij =
kon
koff
=
[xi`j]
[xi][`j]
(4.2)
is the association constant for the virus/antibody binding reaction `j + xi
kon−−→ `j · xi,
and kon and koff are the on and off reaction rate constants. Note that the association
constant represents the fraction bound of antibody/virus complexes in solution and
that
Kij =
3 · IC50ij
3ri + ln(2)− IC50ij , (4.3)
is found by solving Equation (4.6) for one virus/antibody pair for the duration
[t0, tf ] = [0, 3]. Results [22] show that Hill coefficients for CD4 binding site anti-
bodies range from n = 0.9 to n = 1.3, and therefore we justify our simplification by
setting the Hill coefficient n = 1. Our algorithm yields antibody concentrations near
zero and this yields the linear approximation
ψij =
1
Kij
`ij. (4.4)
In addition, the antibodies we consider in our example do not target the same epitope,
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in other words, do not bind competitively to the same sites on the virus, thereby
reducing any coupling between antibody concentrations.
Mutation process. The mutation rate for HIV reverse transcriptase is u =
3 × 10−5 mutations/nucleotide base pair/replication cycle, and the HIV replication
cycle is approximately 2.6 days. We approximate the rate of mutation for a particular
amino acid mutation at a particular location to be 1
na
u(1 − u)k = 1.443 × 10−6 per
replication cycle, where k ≈ 3000 is the size of the genome in residues and na = 19
is the number of amino acids that can be mutated to. Our model supports forward
point mutations and two point mutations. We do not consider back mutations, as the
probability of mutation is negligible. Units of concentration in number of viruses/ml
or number of antibodies/ml are used for states, and time is measured in days. The
standard volume is 1 ml.
4.2.2 Controller synthesis
4.2.2.1 L1 controller synthesis
We synthesize a nominal stabilizing controller using Equation (3.7) comprised of an
antibody pentamix (0.4687,0.7815, 0.6129, 0.6279, 0.8831) µg/ml of (3BC176, PG16,
45-46G54W, PGT128, 10-1074) using the convex program 6 and a robust controller us-
ing (3.8) that consisted of antibody trimix (0.6891,0.6712,1.0706) µg/ml of (3BC176,
4546-G54W, PGT128) using the L1 combination therapy algorithm. These were
generated for the evolutionary dynamics with twenty eight HIV mutants listed in
Table 4.4, Section 4.3.5.
Both antibody pentamix (stabilizing) and trimix (robustly stabilizing) controllers
have similar gains and based on a cursory first glance, one might be believe these have
comparable robustness properties. Indeed, for some simulations of the closed loop
dynamics subjected to random time invariant perturbations in replication and neu-
tralization dynamics, the nominal controller is stabilizing as seen in Figure 4.1. This
is qualitatively consistent with the experimental results [47]. It was shown that with
weekly injections of equal concentrations of the antibody pentamix described above,
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viral loads remained below the limit of detection during an entire treatment course in
mice. Moreover in [47], the presence of N160K-A281T-N332K, T162I-N280Y-N332K
and T162I-N279K-N332K triple mutants were found after continuous antibody pen-
tamix treatment in mice. Our simulation results show that these triple mutants
dominate on the tenth day when the dynamics are destabilized by noise in the case of
the nominally stabilizing controller. In particular, these triple mutants are resistant
to all but one antibody 3BC176 in the pentamix, highlighting the importance of this
antibody in the design of a robustly stabilizing controller. The robustly stabilizing
antibody combination trimix synthesized by our algorithm addresses this particular
dependence — a sparse combination is found that includes 3BC176 at a higher con-
centration and this trimix stabilizes HIV dynamics despite the presence of random
perturbations in the dynamics.
In [47], an antibody trimix of equal concentrations of 3BC176, PG16 and 45-
46G54W was suggested and experimentally shown to produce a decline in the initial
viral load. However, a majority of mice in the experimental study had a viral rebound
to pre-treatment levels, suggesting that in these cases, the virus had evolved mutations
that were resistant to the trimix treatment. To compare the performance of our L1
synthesized controller with gains of (0.6891,0.6712,1.0706) µg/ml of (3BC176, 4546-
G54W, PGT128) to the experimentally studied trimix, we chose equal concentrations
of (3BC176, PG16, 45-46G54W), namely (1, 1, 1) µg/ml to mimic the experimen-
tally derived trimix. We found that even though total antibody concentrations were
larger in our version of the experimental trimix, the robustly stabilizing controller
synthesized by the L1 algorithm nonetheless performed overall better; the closed
loop induced 2-norm was ‖G‖∞ = 0.2941 and induced infinity norm was ‖G‖∞−ind=
0.6533 for the L1 controller versus ‖G‖∞=0.26433 and ‖G‖∞−ind=0.74572 for the
experimental trimix.
4.2.2.2 Performance comparisons between H∞ and L1 controllers
We seek to provide a qualitative comparison between controllers synthesized using the
scalable L1 and the H∞ algorithms. To do this, we adapt the formulation in Section
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Figure 4.1: A. Sum of infected cell populations subject to random time invariant per-
turbations in the replication dynamics for 30 different simulations for (left) a stabiliz-
ing closed loop controller comprised of antibody pentamix (0.4687,0.7815, 0.6129, 0.6279,
0.8831) µg/ml of (3BC176, PG16, 45-46G54W, PGT128, 10-1074) synthesized using pro-
gram (6) and (right) a robustly stabilizing closed loop controller comprised of antibody
trimix (0.6891,0.6712,1.0706) µg/ml of (3BC176, 4546-G54W, PGT128) synthesized using
the L1 combination therapy algorithm. B. (Left) Fraction of mutant infected cell popula-
tions remaining on day 10 for unstable simulations of HIV dynamics subject to noise, after
the application of the antibody pentamix shown in A. (Right) Half maximal inhibitory con-
centrations of antibodies (IC50) with respect to HIV mutants, experimentally found in [47].
IC50 values are proportional to the degree of resistant for each mutant strain.
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3.3.3 to include `1 and `2 regularization terms and solve the following non-convex
problem using our iterative algorithm:
minimize γ + λ1‖`‖1 + λ2‖`‖2
subject to ATclX +XAcl + CTC X
X −γ2I
 ≺ 0
Acl = (A−Ψ(`))
C = 1T
X  0, X diagonal.
(4.5)
We synthesized a nominal stabilizing controller using (3.7), a robust controller
that minimizes the H∞ closed loop norm using (3.8), and a robust controller using
(3.23) that minimizes the L1 closed loop norm for the evolutionary dynamics of the
eighteen HIV point mutants listed in Table 4.4. We found similar gains and robustness
properties for both sparse and full controllers using either algorithm with the notable
difference seen in computational time. Not surprisingly, the L1 algorithm has far
superior performance, beating the runtime for the H∞ synthesis algorithm by four
orders of magnitude (Table 4.1).
We averaged thirty simulations of closed loop evolutionary dynamics subject to
5.5% random time invariant perturbations in the plant dynamics using both sparse
and full support H∞ and L1 controllers. The sparse controller found by the L1 algo-
rithm performed better than the one found by H∞ algorithm, whereas the situation
was reversed for the respective synthesized full support controllers. As previously
mentioned, the motivation for generating sparse controllers for combination therapy
is that number of therapies commonly used in combination to treat a disease is often
limited for clinical reasons. Therefore, the potential for the L1 algorithm to synthesize
controllers that are not only sparse but more robustly stable than H∞ algorithm with
respect to parameter uncertainty and unmodeled dynamics is a desirable feature.
Figure 4.2 shows the relationship between gain sparsity and magnitude of (left)
H∞-induced norm and (right) ∞-induced norm in the synthesis of H∞ and L1 con-
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Controller Gains µg/ml ‖G‖∞ ‖G‖∞−ind Time
3BC176 PG16 45-46G54W PGT128 10-1074
Nominal Stabilizing 0.0125 0.0125 0.0125 0.0125 0.0125 2.7543 8.9786 1.53 s
Full H∞ 0.0550 0.0398 0.1587 0.1767 0.0629 0.1723 0.5988 > 8 hours
Full L1 0.0424 0.0038 0.1125 0.2635 0.0548 0.1786 0.6722 35.803 s
Sparse H∞ 0 0 0.1485 0.1987 0 0.1917 0.6592 > 8 hours
Sparse L1 0 0 0.1175 0.2971 0 0.1766 0.6616 35.803 s
Nominal Stabilizing (28 mutants) 0.4687 0.7815 0.6129 0.6279 0.8831 0.334 0.805 3.76 s
Sparse L1 (28 mutants) 0.6891 0 0.6712 1.0706 0 0.2941 0.6533 30.05 s
Table 4.1: Stabilizing gains found for nominal stabilizing controller, a robust controller
using (3.8) that minimizes the H∞ closed loop norm and a robust controller using (6) that
minimizes the L1 norm of the closed loop system for evolutionary dynamics systems of the
first eighteen HIV point mutants listed in Table 4.4, Appendix.
trollers. Although closed loop H∞ norms remain constant with respect to sparsity
for both types of controller synthesis, the closed loop∞-induced norm decreases with
sparsity for the L1 synthesized controller and increases with sparsity for the H∞
synthesized controllers. This suggests that as expected, the L1 combination therapy
algorithm finds better performing sparse controllers with respect to the ∞-induced
norm than the H∞ controller synthesis. Furthermore, performance guarantees with
respect to the H∞-induced norm are equivalent for both types of controller synthesis.
As a result of computational limitations due to an SDP implementation of the H∞
algorithm, we were were limited to synthesizingH∞ and L1 controllers and comparing
performance for a subset of eighteen mutants from Table 4.4.
These simulations demonstrate that although many stabilizing solutions to the
combination therapy problem exist, the best ones are found when design parame-
ters such as a sparsity, limits on the magnitude of gains, and robustness guarantees
are simultaneously considered. Experimentally searching for these combinations is
infeasible as the number of potential therapies and possible concentrations to con-
sider is experimentally intractable. We propose to guide these experimental activities
with our ability to design and synthesize combination therapy controllers. As such,
one could generate a family of controllers based on “design specifications” tailored not
only the (viral or cellular) composition of the disease, but to explore tradeoffs between
number of therapies used (sparsity), therapy concentrations (magnitude of the gain)
and ability to support pharmacokinetic fluctuations (robustness to perturbations) and
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Figure 4.2: The graph depicts the average H∞ (left) norm and ∞− ind norm as a function
of the sparsity of stabilizing controllers found using either the H∞ or L1 combination ther-
apy algorithms. The graphs depict the average of thirty simulations subject to random time
invariant perturbations of 5.5 % in the plant dynamics found with the H∞ and L1 combi-
nation therapy algorithms for evolutionary dynamics of the first 18 point mutants in Table
4.4, Appendix. (Left) Full support controllers synthesized with the pentamix of antibodies
available: 3BC176, PG16, 45-46G54W, PGT128 and 10-1074 and (Right) Sparse controllers
synthesized with only two antibodies 45-46G54W and PGT128.
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subsequently verify these experimentally.
4.3 Preliminary Experimental Results
4.3.1 Abstract
Recent studies in HIV-1 immunotherapy have revealed that HIV can escape from the
most potent broadly neutralizing antibody (bNAb) monotherapy and combination
therapy. These data suggest a need to develop a methodology that directly addresses
viral heterogeneity and that controls the evolutionary process leading to resistance
in the design of effective bNAb treatment strategies. We developed a computational
model and design tool that solves for candidate combinations and concentrations of
bNAbs while allowing the exploration of trade offs in treatment design, such as lim-
iting the number of bNAbs in the combination, dosage constraints and robustness
to error. We demonstrate successful in vitro validation of our computationally pre-
dicted bNab combinations on heterogeneous viral populations comprised of resistant
mutants. This study provides the first example of how combination anti-HIV bNAb
treatment regimens can be rationally designed to maximize virus neutralization while
minimizing the outgrowth of resistant populations.
4.3.2 Introduction
A challenge inherent to the treatment of chronic HIV infection is the risk that the virus
will evolve to become resistant to treatment methods that comprise the standard of
care. Recent pre-clinical and clinical data in the context of HIV immunotherapy have
shown that HIV can escape from the most potent anti-HIV-1 broadly neutralizing
antibody (bNAb) monotherapies and polytherapies [14, 37, 47, 95]. Heterogeneity
in patient viral populations and the dynamics of evolutionary selection are issues
that need to be explicitly addressed in the design of effective antibody combination
regimens.
The challenge of designing treatment strategies that prevent resistance is one that
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has been studied in both theoretical and experimental contexts. In the case of HIV
and antiretroviral therapy, control theoretic methods have been proposed to delay
the emergence of resistant mutant viruses, with the design of optimal drug scheduling
and dosing strategies [25, 56, 108]. Other computational approaches integrate exper-
imental data and modeling of antiretroviral pharmacodynamics [90], simulation and
analysis of evolutionary dynamics models [31, 40, 87]. A computationally tractable
method for the analysis and design of combination treatment strategies that is based
on an experimental foundation and that allows for the principled exploration of design
tradeoffs is missing.
Our proposed methodology for the rational design of combination therapy ad-
dresses these aforementioned issues, and in addition allows for the ability to quan-
tifiably explore tradeoffs between number of drugs in therapy used in combination,
their concentrations and the robustness of these treatment strategies to pharmaco-
dynamic fluctuations and error. Our algorithm is based on the application of recent
results in optimal control [82, 83] to an HIV evolutionary dynamics model and is con-
structed from experimentally derived antibody resistant phenotypes and their single
antibody pharmacodynamics. This model assumes that individual antibodies when
used in combination have independent, additive neutralization effects on single HIV
mutants, which have been shown to hold for antibodies that bind at orthogonal bind-
ing sites [49], and is applicable in this study. This method represents a first step
towards integrating principled engineering techniques with an experimentally-based
mathematical model to design combination treatment strategies that offer predictive
understanding of evolutionary dynamics and resistance of HIV with in vitro valida-
tion.
4.3.3 Results
Optimization of Combination Antibody Treatment Strategies
Our combination therapy algorithm identifies the smallest number of antibodies
to combine and solves for the concentrations that robustly neutralizes HIV infection
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Figure 4.3: A. Experimentally derived infection timecourse for point mutants YU2-HIV.
B. Experimentally derived neutralization curves for mutants of YU2-HIV with respect to
antibodies 4546-G54W, PGT128. Results of evolutionary dynamics simulations run for
3 days, starting with 1 % infection of monoclonal YU2-WT, for different concentrations
of antibodies 4546-G54W and PGT128, reproducing experimental conditions. C. Degree
of resistance calculated as IC50×maximum neutralization. Replication rates for YU2-HIV
mutants. D. Simulations of evolutionary dynamics for single antibody therapies. Percentage
of virus subpopulations at day 30 for simulations shown.
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subject to the evolutionary dynamics of mutation and selection. The goal is to design
treatment strategies that stop the evolution to resistance or outgrowth of any pop-
ulation of resistant viruses, whether these viruses are pre-existing or occur as part
of a selection process. Another feature of our methodology is that our combination
therapies can quantifiably account for uncertainty and processes that are not a priori
considered, such as experimental error, unmodeled resistance mechanisms [14] and
changes in antibody pharmacokinetics [37]. Mathematical details of our evolutionary
dynamics model and combination therapy algorithm can be found in Section 4.3.4.
In order to apply our algorithm, we first constructed our evolutionary dynamics
model of replication, mutation and selection based on single antibody pharmacody-
namics data derived for eighteen YU2-NL43 HIV-1 clade B Env mutants and five
antibodies NIH4546G54W, PGT128, 8ANC195, PG9 and 10E8. We performed sim-
ulations and validated our experimentally derived evolutionary dynamics model both
for consistency in replicating our own neutralization assays and also in predicting
evolution to resistance (Figure 4.3B). For an initial population of monoclonal wild
type YU2 exposed to a constant dose of a single antibody, we showed that mutants
that evolved after 30 days from our simulations (Figure 4.3D) were consistent with
previous evolution studies in humanized mice [14, 37, 47].
We then applied our design method to our experimentally derived evolutionary
dynamics model to solve for the smallest set of antibody combinations and concen-
trations to neutralize infection. Our algorithm allows for the specification of hard
constraints such as maximum allowable individual or total antibody concentrations,
and soft constraints such as trade offs between robustness to uncertainty and dose
minimization. Our methodology, which is based on the application of robust con-
trol theory, guarantees that if a combination therapy is found, it will be effective
in neutralizing infection and controlling evolution to resistance for any mixture of
viruses, given some knowledge of each of viruses in the mix. We specified that the
total antibody concentration be less than 5 µg/ml and found two equivalently robust
quadruple combinations that consisted of (1, 0, 1.5, 1.25, 1) µg/ml and (1, 1, 0, 1.5,
1) µg/ml of (45-46G54W, PGT128, 8ANC195, 10E8, PG9). Simulations of our evolu-
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Figure 4.4: A. Schematic of growth, mutation and drug selection with respect to a population
dynamics model. B. A deterministic differential equation model representing the population
dynamics of replication, mutation of infectious units and their neutralization by antibodies.
C. A schematic of the control system representing the combination therapy design problem,
with examples of design constraints that can be specified. HIV replication and mutation
dynamics are the unstable evolutionary process that we wish to control by finding effective
combinations and concentrations of antibodies given particular treatment design constraints.
tionary dynamics model show that when our system is subjected to uncertainty, these
combinations are still able to neutralize infection of a mixed population of resistant
viruses (Figure 4.5). This particular example highlights that the best combinations
are not necessarily the ones that include all antibodies, but ones that are designed
with evolutionary dynamics and robustness in mind.
In Vitro Validation of Predicted Antibody Combinations.
To experimentally validate our predictions, we used an in vitro fluorescence based
assay that exposed a mixture of wild type and mutant HIV infected cells to our
predicted combination antibody therapies, where each mutant was resistant to at
least one of the antibodies in the combination (Figure 4.5). Testing the combination
antibody therapies predicted by our algorithm on heterogeneous viral populations
allows us to verify that these regimens are agnostic to initial conditions consisting of
resistant viral populations, as long as there is prior knowledge on their replication
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fitness and single antibody response.
4.3.4 Materials and Methods
Mutagenesis, Virus Production and Cells. Site directed mutagenesis and as-
sembly PCR were used to generate YU2-NL43 Env mutants. YU2-NL43 was modified
using unique restriction sites EcoRI and XhoI. Inserts were generated by PCR using
primers EcoRI-CF (5’-GCCAGCCAGAATTCTGCAACAACTGCTGTTTATCCAT
TTCAG-3’) and XhoI-CR-(5’-GCGTCGACCTCGAGATACTGCTCCCACCCCATC-
3’) and individual sense and antisense mutagenesis primers corresponding to YU2-
NL43 mutants listed in the table below (Appendix). Escherichia coli One Shot STBL3
Chemically Competent cells (Life Technologies) were used to propagate proviral plas-
mids during a 16 hour incubation at 30◦ C. Stocks were prepared using a DNAMidi kit
(Zymo Research). All gene constructs were verified by complete sequencing of gp160.
Cell-free virus was produced by transfection of HEK293T cells with YU2-NL43 virus
coding plasmid using BioT (Bioland Scientific). Viral supernatant was harvested at
48 h post transfection, filtered through a 0.5 µm filter and aliquots were stored at
-80◦ C. Stock concentrations were quantified by p24 enzyme-linked immunosorbent
assay (ELISA) (Cell Biolabs). The YU2 Env/NL43 plasmid was obtained from the
Nussenzweig lab, Rockefeller University. The green fluorescent protein (GFP) re-
porter T-cell line GXR-CEM is previously described in [11] was obtained through
AIDS Research and Reference Reagent Program, National Institute of Allergy and
Infectious Diseases, National Institutes of Health.
Protein Expression and Purification. Antibodies were transiently expressed
in HEK293T/17 cells or suspension HEK 293-6E cells (National Research Coun-
cil Biotechnology Research Institute, Montréal, QC, Canada) using 25-kDa linear
polyethylenimine (Polysciences) for transfection. Supernatants were passed over Mab-
Select SuRe protein A resin (GE Healthcare) or Protein G Sepharose 4 Fast Flow (GE
Healthcare) and eluted by using pH 3.0 citrate or glycine buffer, and then immedi-
ately neutralized. Antibodies were further purified by size exclusion chromatography
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Figure 4.5: A. Combination therapy experiment showing the timecourse of infection after
administering two different antibody combinations that were solved with the combination
therapy algorithm, for two different initial conditions: YU2-WT and a mix of YU2-WT and
of YU2-(N160T,N276S, N279K, S334N, T278A, T278I) each one resistant to one or more
of (45-46G54W, PGT128, 10E8, 8ANC195, PG9). Infection timecourse shown for both
initial conditions. B. Thirty simulations of evolutionary dynamics subject to random time
invariant perturbations of 8% in the system dynamics, given robust combination therapy 1
(CT1) (Blue), a robust combination therapy 2 (CT2). The magenta line corresponds to the
evolutionary dynamics of the unperturbed system.
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using a Superdex 200 or 75 10/300 GL column.
In Vitro Replication and Neutralization Assays. To initiate infection for
both replication and neutralization assays, GXR-CEM cells at 4× 105 cells/ml were
infected with 200 ng YU2-NL43 (HIV) virus stock in the absence of antibody and
incubated for three days at 37◦ C. Two days after infection, uninfected GXR-CEM
cells at 2 × 105 were pre-treated with 0, 0.02,0.08, 0.4,1.6, 6.4, 20, 80 µg/ml of sin-
gle PGT128, NIH45-46G54W , 8ANC195, PG9 and 10E8 antibodies. Three days after
initial infection with cell free virus, the infected GXR-CEM were washed and added
to a final concentration of 1 % GFP-expressing donor cells to uninfected pre-treated
GXR-CEM cells. For the neutralization assay, a constant concentration of antibody
was maintained for each sample for three days following secondary infection. Infec-
tion was determined by measuring GFP reporter gene expression in the absence of
antibodies measured daily for four days following secondary infection. Neutralization
was determined by measuring the reduction in GFP reporter gene expression in the
presence of antibodies PGT128, NIH4546G54W, 8ANC195, PG9 and 10E8 daily for
three days. Nonlinear regression analysis was used to calculate the concentrations
at which half-maximal inhibition was observed (IC50 values) by fitting the observed
neutralization to the expression γ`n/(`n+IC50n), where γ is the maximum achievable
neutralization, ` is the antibody concentration and n is the Hill coefficient.
In Vitro Combination Therapy Assays. To initiate infection for the mixed
mutant initial condition, GXR-CEM cells at 4 × 105 cells/ml were infected with
(80, 20, 20, 20, 20, 20) ng with each of YU2-NL43-(WT, S334N, N279K, N276S,
T278I,N160T,T278A) virus stock in the absence of antibody and incubated for three
days. Three days after initial infection with cell free virus, the infected GXR-CEM
were washed and added to a final concentration of 1 % GFP-expressing donor cells to
uninfected pre-treated GXR-CEM cells. On each day after infected donor addition,
cell aggregates were broken up by gentle repeated pipetting and measured by FACS
for four days. Infection conditions were calibrated so that the number of uninfected
target cells would not be limiting and infection would not interfere with proliferation
of uninfected cells.
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Flow cytometry and Dynamical System Parameter Estimation. Flow
cytometry data was collected with a MACSQuant flow cytometer and transformed to
a python format using the FlowCytometryTools python package (Gore lab, MIT). An
automated gating and analysis software module written in python was developed to
process large sets of flow cytometry data. All parameter estimation was done using
the python scipy.optimize module. Dynamical system replication rates for YU2-NL43
mutants were calculated by fitting an exponential growth function x(t) = x(0)ert.
Neutralization rates were calculated by fitting a Hill equation γ `n
`n+IC50n , where ` is
antibody concentration, γ is the maximum neutralization, n is the Hill coefficient, and
IC50 is half maximal inhibitory concentration curves. Mutation rates were calculated
using the mutation rate for HIV reverse transcriptase µ = 3 × 10−5 mutations/base
pair/replication cycle [] for the specific YU2-NL43 mutants that were constructed.
Model of HIV evolutionary dynamics. We use a deterministic model of HIV
evolutionary dynamics to model replication, mutation and neutralization:
x˙i = riqiixi +
n∑
k 6=i
riqikxk −
m∑
j=1
γij
`
nij
j
`
nij
j + IC50
nij
xi, (4.6)
where xi ∈ R+ is the concentration of infectious mutant i, `j ∈ R is the antibody
concentration in µg/ml (assumed to remain at constant concentrations throughout),
ri is the replication rate of mutant i, and qik is the probability that mutant k mutates
to mutant i (note that qii is the probability of no mutation occurring). The rates ri
can be viewed as the infection rates of mutant i without the effect of the antibody.
γij and nij are the maximum achievable neutralization and the Hill coefficient for
the neutralization of mutant i by antibody j. This model assumes that individual
antibodies when used in combination have independent, additive neutralization ef-
fects. This does not overly constrain our problem as we generally consider antibodies
that bind at orthogonal binding sites which have been shown to have independent,
additive effects when used in combination.
Combination Therapy Algorithm. We applied the combination therapy algo-
rithm for nonlinear pharmacodynamics described in Section 3.5.3, using the model of
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evolutionary dynamics described above, with parameters listed in Tables 4.2 and 4.3,
Appendix. We first generated a set of 10000 pharmacodynamic modes that represent
piecewise linearizations of the neutralization curves. Using our sparse mode reduction
algorithm (3), we reduced this number to 397 modes and used these as input to the
combination therapy algorithm. Several design constraints were defined prior to run-
ning the combination therapy algorithm: 1) the total antibody concentration be less
than 5 µg/ml, 2) the combination therapy must be robust to perturbations. Given
these constraints, the algorithm solved for two quadruple antibody combinations with
equivalent robustness levels.
4.3.5 Appendix
R 45-46G54W PGT128
max IC50 n max IC50 n
YU2-WT 0.646 0.94234 0.06636 1.3945 0.94924 0.12469 1.4692
YU2-N160K 0.619 0.91966 0.14658 2.9826 0.98216 0.12977 0.65651
YU2-N160S 0.704 0.94892 0.055377 0.99516 0.90636 0.29987 1.4888
YU2-N160T 0.637 1 0.030035 4.3297 0.85211 0.19524 2.5482
YU2-N160Y 0.66 0.94412 0.13862 4.0697 0.95484 0.14137 3.4386
YU2-N276S 0.724 0.74572 0.27784 1.4011 0.87891 0.45284 1.4061
YU2-N279H 0.426 0.8932 0.027408 7.9821 1 0.020018 10.947
YU2-N279K 0.362 0.18648 13.084 6.4848 0.88866 0.079372 1.0901
YU2-N332S 0.503 0.97656 0.031375 4.5121 0.73823 19.925 10.703
YU2-N332T 0.689 0.94674 0.13681 2.7212 0.1366 0.18446 4.7561
YU2-S334N 0.562 0.90953 0.13689 2.1111 0 7.0653 0.93399
YU2-S334Y 0.42 1 0.25627 0.84276 0.37354 19.99 9.7835
YU2-T162A 0.734 1 0.12631 1.7346 0.97392 0.1324 1.4749
YU2-T162I 0.643 0.96232 0.032941 3.1854 0.96036 0.20933 1.618
YU2-T162P 0.655 0.91681 0.13396 2.2804 1 0.16072 1.1002
YU2-T278A 0.72 0.96287 0.030657 5.2389 0.94765 0.54778 1.9417
YU2-N301T 0.542 0.91602 0.037664 5.6922 0 1.2506 0.82346
YU2-T278I 0.713 0.95487 0.052562 1.558 0.96781 0.17467 1.0706
Table 4.2: Replication rates per day and neutralization curve parameters for the indicated
antibodies on YU2-NL43 mutant viruses.
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10E8 8ANC195 PG9
max IC50 n max IC50 n max IC50
YU2-WT 0.94486 0.060457 0.47707 0.9347 0.12696 1.7026 0.45589 0.49713 0.70523
YU2-N160K 0.96615 0.022256 0.559 0.49399 1.5986 9.8458 0.3395 0.091707 0.30884
YU2-N160S 0.84544 0.60074 0.37193 0.98259 0.074471 0.64653 0.59807 0.074839 0.41778
YU2-N160T 0.92565 0.013653 0.77443 0.91221 1.5885 11.62 0.59807 0.074839 0.41778
YU2-N160Y 0.95313 0.0073578 1.0627 1 0.051382 0.31669 0.68767 1.4407 1.375
YU2-N276S 0.94657 0.70223 0.51266 0.80248 0.14602 7.3062 0.70541 0.67781 0.86789
YU2-N279H 0.97946 0.0057117 2.3761 0.97464 0.14855 7.9667 0.9263 0.057702 0.92412
YU2-N279K 0.90362 0.011933 0.69676 0.81632 0.22242 0.60999 0.9263 0.057702 0.92412
YU2-N332S 0.95397 0.22654 0.49865 0.94235 0.03849 1.1722 0.76037 0.30023 0.57322
YU2-N332T 0.96289 0.050848 0.43029 0.90555 0.16991 1.0793 0.71449 4.2677 0.9406
YU2-S334N 0.85623 0.10818 1.0919 0.85539 0.65643 1.9121 0.59587 11.837 7.5342
YU2-S334Y 0.87005 0.065392 1.0087 0.84908 0.12062 0.92592 0.6376 12.24 1.4706
YU2-T162A 0.95998 0.24036 0.51997 0.89124 0.15116 0.82269 0.58197 0.25439 0.55699
YU2-T162I 0.93713 0.24137 0.58461 0.82959 0.11562 0.79189 0.45277 0.075214 0.4691
YU2-T162P 0.9602 0.013527 0.54256 0.83843 0.11323 0.88195 0.55945 19.838 11.047
YU2-T278A 0.89614 0.16974 0.43169 0.64413 0.074199 0.50969 0.84999 9.6801 7.6016
YU2-N301T 0.90295 0.025051 0.62866 0.75917 0.86499 7.1084 0.69971 20.099 11.154
YU2-T278I 0.83407 6.4431 4.9855 0 2.6138 0.049654 0.86148 0.46376 0.42271
Table 4.3: Neutralization curve parameters for the indicated antibodies on YU2-NL43 mu-
tant viruses.
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Antibody associated Mutation 3BC176 PG16 45-46G54W PGT128 10-1074
escape mutants IC50 µg/ml IC50 µg/ml IC50 µg/ml IC50 µg/ml IC50 µg/ml
WT 0.319 0.612 0.024 0.169 0.312
3BC176 G471R 0.159 0.154 0.008 0.02 0.091
PG16 N160K 0.145 50 0.007 0.086 0.155T162N 0.154 50 0.013 0.166 0.175
45-46G54W N279H 0.209 0.294 50 0.064 0.177N280Y 0.276 0.145 50 0.031 0.126
PGT128 or 10-1074
N332K 0.232 0.988 0.017 50 50
N332Y 0.269 0.632 0.01 50 13.596
S334N 0.218 0.615 0.02 50 7.308
Passenger mutations
Y61H 0.243 0.285 0.015 0.098 0.26
E102K 0.173 0.341 0.023 0.11 0.207
N295S 0.347 0.5 0.017 0.145 0.159
I311M 0.23 2.67 0.013 0.248 0.253
S365L 0.26 0.273 0.009 0.045 0.153
G366E 0.187 0.167 0.001 0.021 0.074
I371M 0.2 0.303 0.013 0.064 0.164
N413K 0.188 0.557 0.014 0.032 0.109
E429K 0.146 0.503 0.017 0.082 0.167
N295S-G366E-N413K 0.222 0.131 0.001 0.012 0.021
tri-mix T162I-G458D 0.275 50 14.33 0.012 0.047T162N-N280Y 0.138 50 50 0.027 0.079
penta-mix
N160K-N280Y-N332K 0.146 50 50 50 50
N160K-A281T-N332K 0.1 50 50 50 50
T162I-N280Y-N332K 0.13 50 50 50 50
T162I-N279K-N332K 0.149 50 50 50 50
Signature + Passenger
T162I-Y61H 0.156 50 0.014 0.088 0.115
T162N-V430E 0.167 50 0.003 0.037 0.106
N280Y-A174T 0.064 0.138 50 0.01 0.021
N332S-N413K 0.181 0.526 0.017 50 50
Estimated Mutations
N160K-N280Y 0.276 50 50 0.086 0.155
N160K-N332K 0.232 50 0.017 50 50
N280Y-N332K 0.276 0.988 50 50 50
N295S-G366E 0.347 0.5 0.017 0.145 0.159
N295S-N413K 0.347 0.557 0.017 0.145 0.159
G366E-N413K 0.188 0.557 0.014 0.032 0.109
Table 4.4: IC50 values for the indicated antibodies on YU2 mutant viruses found in contin-
uous antibody mono therapy experiments conducted by the Nussenzweig lab at Rockefeller
University [47]. The trimix of antibodies is : 3BC176,PG16,45-46G54W, the penta-mix is
3BC176, PG16, 45-46G54W , PGT128 and 10-1074. Estimated two point mutations repre-
sent intermediary mutations needed for our model but not included in experimental results
in [47]. The IC50 values were taken to be the maximum IC50 of both mutations.
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Chapter 5
Summary and Future Directions
This thesis describes the development, analysis and implementation of novel math-
ematical models and control theoretic algorithms for the prediction and control of
evolutionary dynamics disease models. In particular, we apply these methods to
study the evolution of HIV resistance in the presence of broadly neutralizing anti-
body therapy and to synthesize effective combination treatment strategies for effective
control. We show that our models and techniques are validated with our own exper-
imental studies as well as in agreement with previous studies. The contributions of
this thesis are summarized below.
Evolutionary Dynamics on Computationally Derived Fitness
Landscapes
We develop two computational models to reason about HIV resistance to antibody
therapy. Our first method is an extension of the least absolute shrinkage and selection
operator (LASSO) that serves to identify potential escape mutations from neutraliza-
tion data. Our model is applied to HIV and antibody neutralization data and uncovers
key residue locations and substitutions that are at the basis of neutralization, that
are verified by previous or our own experimental studies.
Our second computational model allows us to reason about the dynamics of evolu-
tion on computationally generated fitness landscapes. It is developed from biophysi-
cal first principles that link differences in binding energies with changes in replication
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and the effect of selective pressure. We apply our approach to an HIV evolutionary
dynamics model that incorporates infection and antibody neutralization dynamics,
a mutation process, and a method that uses energy minimization calculations on
structural information to quantify fitness differences between sensitive and resistant
strains. We show that there is agreement between our model and previous murine
studies of HIV evolution in the presence of antibody therapy. A useful extension is
to include a mutational model that captures the dynamics of two mutations or more
to provide further predictive power.
Robust Control of Evolutionary Dynamics
We present three algorithms for the principled design of targeted combination drug
treatment strategies that explicitly account for the evolutionary dynamics of a generic
disease model, where the drugs under consideration are non-interacting and exhibit
independent additive effects. These algorithms allow the designer to quantifiably ex-
plore tradeoffs between number of therapies used (controller sparsity), therapy concen-
trations (magnitude of the gain) and ability to support pharmacokinetic fluctuations
(robustness to perturbations).
Our first algorithm proposes a general iterative method that uses an H∞ robust
control approach to design targeted combination therapy concentrations and is effec-
tive in generating robustly stabilizing controllers. Our second algorithm addresses
large scale systems concerns lacking in the first algorithm, presenting a scalable solu-
tion to the combination therapy problem by reformulating it as a second order cone
program (SOCP), with robustness guarantees addressed by minimization of the in-
duced L1 norm. Our third algorithm solves the combination therapy problem subject
to the same design constraints (sparsity of the drug combination, maximum dosage
and robustness constraints) formulated as an SOCP while addressing the nonlinear
dynamics of individual drugs and of their combinations.
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Engineering Antibody Treatment Strategies to Control HIV
We demonstrate our ability to control the evolution to resistance of HIV in the pres-
ence of antibody therapy, through the application of the combination therapy algo-
rithms developed in Chapter 3 as applied to experimental data derived from recent
published studies [14, 22, 47]. Specifically, we synthesize combination treatments and
compare the respective H∞ and the L1 combination therapy algorithms with respect
to their performance and robustness to biologically relevant uncertainty models and
unmodeled dynamics.
We also develop an in vitro experimental methodology and demonstrate that
the antibody treatment strategies synthesized with the nonlinear pharmacodynamics
combination therapy algorithm described in Section 3.5.3 controls infection despite
the presence of a mixed initial population of viruses, most of which are resistant to at
least one antibody in the mix. Additional work is in progress to further experimentally
validate other combination strategies synthesized by our algorithm.
Implications
With the expansion of molecular data associated with human disease and the rapid
discovery of new targeted therapies, the application of individualized medicine is
becoming a more tangible prospect. The ability to do this not only requires that
health care providers have access to large sets of disease-related data but that they
are also equipped to use it to engineer effective treatments for their patients.
The research in this thesis centers around the idea that precision medicine is
ultimately the combination of multiple disciplines: the understanding of biomolecular
foundations and dynamics of disease, the consolidation and analysis of large sets of
molecular and clinical data, and the ability to incorporate these complementary views
on disease to engineer treatment strategies tailored to a patient’s disease population,
pharmacokinetic limitations all while being robust to evolution to resistance. Our
goal was to provide a theoretical and computational foundation for a set of predictive
tools to help reason about the nature of genetic alterations that lead to resistance, the
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disease dynamics leading to escape from targeted therapy and to synthesize treatment
strategies to control evolution of disease. The methods presented here are applied to
the prediction and control of HIV resistance in the presence of antibody therapy, but
are currently being extended to address tumor heterogeneity and control evolution in
cancer.
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